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ABBREVIATIONS
^MAX apparent number of binding sites
DTG 1,3-di(2-tolyl)guanidine
ED50 effective dose50, the dose which causes the desired effect in 
50% compared to drug-induced effect in control animals
EPS extrapyramidal side effects
5-HT 5 -hydroxytryptamine
IC50 50% inhibitory concentration
i. p. intraperitoneal(ly)
KD dissociation constant
NMDA N-methyl-D-aspartic acid
PCP phencyclidine
3-PPP 3 -(3 -hydroxypheny 1)-N-n-propyl-piperidine
s. c. subcutaneous(ly)
(±)-SKF 10,047 (±)N-allyl-normetazocine
TCP 1 - [ 1 -(2-thienyl)cyclohexyl]piperidine
8
1. INTRODUCTION
Compounds having antipsychotic activity belong to a chemically heterogenous group 
of drugs. The blockade of dopamine D2 receptors is a common feature of these drugs 
and a necessary requisite to treat positive symptoms of schizophrenia (Seeman, 1980; 
Richelson, 1984). Long-term administration of antipsychotic drugs such as 
chlorpromazine and haloperidol is accompanied with the development of 
extrapyramidal side effects (EPS) ranging from acute dystonia and drug-induced 
parkinsonism to tardive dyskinesia. Therefore, a substantial effort has been directed 
to develop new antipsychotic drugs lacking EPS. Recently Seeman and Van Tol 
(1994) have proposed the hypothesis that effective antipsychotic medication without 
disabling EPS requires blockade of more than one receptor in the brain. Indeed, 
risperidone and clozapine, blocking dopamine D2, 5-hydroxytryptamine 5-HT2A, and 
5-HT2C receptors do not cause significant EPS but potently ameliorate positive and 
negative symptoms of schizophrenia (Leysen et al., 1993).
In 1976, Martin developed a new functional classification of opioid receptors 
according to action of various drugs in spinal dogs (Martin et al., 1976). 
Psychotomimetic action of SKF 10,047 in dogs was attributed to sigma opioid 
receptors (Martin et a l, 1976). However, the subsequent studies did not confirm 
belonging of these receptors to opioid receptors since unselective opioid antagonist 
naloxone was ineffective against SKF 10,047 (Iwamoto, 1981; Brady et al., 1982; 
Slifer & Balster, 1983; Katz etal., 1985). Moreover, interaction of SKF 10,047 with 
two distinct binding sites was established in the radioligand binding studies. SKF 
10,047 was fully active at NMDA-gated channels and haloperidol-sensitive sigma 
receptors (Zukin & Zukin, 1979; Tam, 1983). Therefore, the psychotomimetic action 
of SKF 10,047 can be mediated by both of these binding sites in the brain (Itzhak & 
Alerhand, 1989; Itzhak & Stein, 1990).
Sigma receptors are characterized by insensitivity to opioid antagonist naloxone 
and also by extremely high affinity for haloperidol, a potent antipsychotic drug 
(Pasternak et a l, 1981; Brady et a l, 1982; Slifer & Balster, 1983; Tam & Cook, 
1984; Katz et a l, 1985; Itzhak, 1988). Neurotransmitters dopamine and 5- 
hydroxytryptamine are lacking major activity at sigma receptors (Tam & Cook, 1984; 
Weber et a l, 1986). Although little is known about the physiological functions of 
sigma receptors, several lines of evidence suggest the involvement of these receptors 
in the action of antipsychotic drugs (Deutsch et al., 1988). It is now clear that several 
antipsychotic drugs have a significant affinity for sigma receptors, often greater than 
their affinity for dopamine receptors (Tam, 1983; Tam & Cook, 1984; Largent et a l,
1988). There is a growing body of evidence about anatomical and functional 
interaction between sigma receptors and dopaminergic systems (Graybiel et al., 1989; 
Taylor et al., 1990; Walker et al., 1990). Sigma receptors are involved in the control 
of the firing rate of dopamine neurons and release of dopamine from neuronal 
terminals (Berkowitz, 1974; Wachtel & White, 1988; Steinfels & Tam, 1989;
5
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Steinfels et a l 1989; Taylor et a l 1990). Stimulation of sigma receptors increases 
release of dopamine, whereas blockade of these receptors decreases activity of the 
dopaminergic system.
Recently, involvement of glutamate in the action of antipsychotic drugs has been 
suggested. Glutamate is also shown to contribute to the control of dopamine release 
in various brain structures (Whitton et al., 1994). Glutamate released from the 
corticostriatal terminals seems to have a strong influence on the dopaminergic 
neurotransmission in the striatum (Martinez-Fong et al., 1992; Whitton et a l 1994). 
One subtype of glutamate-gated channels, N-methyl-D-aspartate (NMDA) channel, 
is believed to be involved in psychotomimetic action of phencyclidine-like compounds 
(Javitt & Zukin, 1991). Phencyclidine and related compounds block these channels 
in non-competitive manner (Wong et al., 1986). The antipsychotic compound 
clozapine also interacts with NMDA-gated channels both in radioligand binding and 
behavioural experiments (Janowsky & Berger, 1989; Tiedtke et a l , 1990). It has been 
even claimed that effectiveness of clozapine against negative symptoms of 
schizophrenia might be linked to its interaction with NMDA-gated channels (Tiedtke 
eta l., 1990; Schmidt etal., 1991).
The present study aimed to extend our understanding of the mechanism of action 
of antipsychotic drugs. We attempted to find out to what extent the various brain 
receptors (dopamine, 5-hydroxytryptamine, NMDA-gated channels and sigma 
receptors) are involved in the action of antipsychotic drugs. Since mainly acute 
experiments have been employed to date in the study of the effects of antipsychotic 
drugs, we made an attempt to use a long-term model of psychotic behaviour in 
laboratory animals. In this model, repeated administration of apomorphine, an 
unselective dopamine agonist, was used to mimic psychotic state in the rat.
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2. REVIEW OF LITERATURE
2.1. Properties of typical and atypical antipsychotic drugs
Antipsychotic drugs are classified as typical or atypical according to their clinical and 
pharmacological effects. The similarities and differences of these two groups of drugs 
are summarized in Table 1.
Antipsychotic effect of typical antipsychotic drugs is accompanied with a high 
probability of occurrence of extrapyramidal side effects (EPS) in man (Table 1). 
Catalepsy is believed to be the rodent equivalent of EPS. Atypical antipsychotic 
drugs, on the contrary, are unlikely to cause these motor disturbances. It has been 
believed that EPS is a prerequisite for antipsychotic action (Mattke, 1968). However, 
recent studies have shown that several effective antipsychotic drugs do not induce 
EPS.
Many animal tests to reveal antipsychotic drugs are based on the inhibition of 
dopamine agonist-induced behaviour. For example, apomorphine-induced climbing 
test in mice is inhibited by low doses of all classes of antipsychotic drugs, including: 
phenothiazines, butyrophenones, thioxanthenes, butaclamol, clozapine, and 
benzamides. Higher doses of typical antipsychotic drugs are needed to block the 
apomorphine- and amphetamine-induced hypermotility in rodents and stereotyped 
behaviour in rats. Atypical antipsychotic drugs, in contrast, are almost ineffective 
against dopamine agonist induced stereotyped behaviour but they efficiently block the 
hyperlocomotion induced by amphetamine or apomorphine (Table 1).
Besides behavioural tests reflecting the increased stimulation of dopamine 
receptors, the conditioned avoidance paradigm has been used to study antipsychotic 
drugs. Typical antipsychotic drugs disrupt the development of conditioned avoidance. 
By contrast, atypical antipsychotic drugs are completely ineffective in this study 
design (Table 1).
Acute treatment with the classical antipsychotic drugs increases spontaneously 
active dopamine neurons in the substantia nigra (A9) and ventral tegmental area (A10). 
Their repeated administration causes opposite action — decreases the number of 
spontaneously active dopamine neurons in these two brain regions. Acute and long­
term treatment with atypical antipsychotic drugs affects only the electrical activity of 
A10 neurons (Table 1). The selective action on the dopamine neurons in the ventral 
tegmental area is a possible reason why atypical drugs do not induce EPS.
All typical antipsychotic drugs have significant affinity for dopamine D2 
receptors, whereas the activity of atypical drugs on dopamine D2 receptors is variable.
6
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T a b l e  1
Comparative effects of typical and atypical antipsychotic drugs
Effect Typical antipsychotic Atypical antipsychotic
drugs (e.g., haloperidol, drugs (e.g., clozapine, 
chlorpromazine) sulpiride, thioridazine,
remoxipride)
Extrapyramidal side effects high probability low probability
in man
(Stiile et al, 1971; Costall & Naylor, 1975; Janssen & 
Van Bever, 1978; Niemegeers & Janssen, 1979)
Catalepsy in laboratory 
animals
Apomorphine- and
amphetamine-induced
hyperlocomotion
Blockade of amphetamine- 
and apomorphine-induced 
stereotypy
Suppression of conditioned 
avoidance response
Regional selectivity for 
dopamine neurons
Affinity for dopamine D2 
receptors
high low
(Stiile et al., 1971; Costall & Naylor, 1975; Janssen & 
Van Bever, 1978; Niemegeers & Janssen, 1979; Worms 
& Lloyd, 1979)
yes yes
(Puech et al., 1976; Simon & Puech, 1979; Bischoff et 
al., 1988)
yes no
(Puech et al., 1976; Simon & Puech, 1979; Robertson & 
MacDonald, 1984)
yes no
(Worms et al., 1983; Blackburn & Phillips, 1989; 
Bruhwyler et al., 1990; Britton et al., 1992)
both A, and A10 A10
(White & Wang, 1983; Hand et al., 1987) (White & 
Wang, 1983; Freeman & Bunney, 1987; Hand et al., 
1987)
high variable
(Seeman, 1980; Richelson, 1984)
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2.2. Interactions of antipsychotic drugs with neurotransmitter 
systems and their receptors
Dopaminergic system and dopamine receptors are proposed to be the primary targets 
for the action of antipsychotic drugs (Mortimer, 1994). However, other 
neurotransmitters are also affected by antipsychotic drugs. Below a short review is 
given about the role of some of these neurotransmitters in the action of antipsychotic 
compounds.
2.2.1. Dopamine
Dopaminergic neurons innervating all major parts of brain arise from cell bodies 
located in the substantia nigra (area A9), ventral tegmental area (area A]0), and 
hypothalamus (area A12 and A13). These neurons form major dopaminergic pathways: 
nigrostriatal (A*,), mesolimbic (A10), mesocortical (A10), and tuberoinfundibular (A12 
and A]3) tracts (Dahlström & Fuxe, 1964). The mesolimbic and mesocortical 
dopamine systems are considered as the main sites for antipsychotic action of drugs, 
whereas hormonal and motor impairments are mediated by the tuberoinfundibular and 
nigrostriatal tracts respectively.
The original pharmacological classification divides dopamine receptors into two 
major groups and five currently cloned dopamine receptors fall into these classes 
(Seeman & Van Tol, 1994). The D,-like receptors include D, and D5, while the 02- 
like receptors include D2, D3 and D4 (Seeman & Van Tol, 1994).
Dopamine D2 receptor blockade, a common feature of all known antipsychotic 
drugs, is believed to be a basic mechanism to treat positive symptoms in 
schizophrenia (Seeman, 1980; Richelson, 1984). As mentioned above, the 
antipsychotic activity of drugs is presumably the result of blockade of the dopamine 
D2 receptors in the mesolimbic system, while the blockade of dopamine D2 receptors 
in the striatum is related to EPS (Carlsson, 1978). Therefore, drugs with higher 
selectivity for dopamine D2 receptors in the mesolimbic area are less likely to induce 
EPS and catalepsy. They display significantly higher selectivity against apomorphine- 
induced hyperlocomotion compared to stereotypies elicited by dopamine agonists. 
Raclopride and remoxipride, new antipsychotic drugs with selectivity for dopamine 
D2 receptors, differ from haloperidol and chlorpromazine by their markedly higher 
potency against apomorphine-induced hyperlocomotion (ögren et al., 1986). 
Relatively higher doses of raclopride and remoxipride were needed to produce 
catalepsy, indicating lower potential to produce EPS (Hillegaart & Ahlenius, 1987; 
Fardeetal., 1989).
The role of dopamine D, receptors in the action of antipsychotic drugs should 
also be considered. Several studies suggest that the blockade of dopamine D, 
receptors is important in the mechanism of action of atypical antipsychotic drugs
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(Chipkin & Latranyi, 1987; Alter et al., 1988; Imperato & Angelucci, 1989). The 
repeated administration of SCH 23390, a selective dopamine D, receptor antagonist, 
caused depolarization inactivation of A10 dopamine cells in the same way as atypical 
antipsychotic drugs (Goldstein & Litwin, 1988).
Seeman and Van Tol (1994) suggested that pharmacotherapy of schizophrenia 
may be improved by the selective blockade of new subtypes of dopamine receptors 
(D3, D4). Clozapine is most active at dopamine D4 receptor subtype (Van Tol et al., 
1991, 1992; Meltzer & Gudelsky, 1992). Moreover, the sixfold elevation of the 
density of dopamine D4 receptors was described in patients suffering from 
schizophrenia (Seeman et al., 1993). Dopamine D3 receptors are mainly located in the 
mesolimbic structures, which are important in the control of motivations (Bouthenet 
e ta l., 1991; Van Tol e ta l., 1991; Sokoloff eta l., 1992).
2.2.2. 5-Hydroxytryptamine
5-Hydroxytryptamine (5-HT) is widely distributed throughout the central nervous 
system. The neurons located in the brainstem raphe nuclei innervate both forebrain 
and spinal cord. The recent classification divides 5-HT receptors into at least seven 
groups with several subtypes (Humphrey & et al., 1993). Abnormalities in 5-HT-ergic 
transmission may be implicated in the pathogenesis of several mental disorders 
including major depression and schizophrenia (Ohuoha et al., 1993).
Several clinically potent antipsychotic drugs have significant activity both at 
dopamine D2 and 5-HT2 receptors. Some of them display even higher selectivity for 
5-HT2 than for D2 receptors (Meltzer et al., 1989). For example, clozapine had nearly 
50 times and risperidone 20 times higher affinity for 5-HT2 than they do to dopamine 
D2 receptors (Leysen et al., 1993). A hypothesis has been presented that high affinity 
of antipsychotic drugs for 5-HT2 receptor reduces the risk of development of EPS, and 
it might have a role in alleviation of negative symptoms of schizophrenia resistant to 
other antipsychotic drugs (Leysen et al., 1988; Gelders et al., 1990). Moreover, 5- 
HT2 antagonists reduce the antipsychotic-induced catalepsy in rats (Balsara et al., 
1979; Hicks, 1990). Differently from typical antipsychotic drugs, the administration 
of atypical compounds changes 5-HT turnover in the brain structures (Csemansky et 
al., 1993).
2.2.3. Sigma receptors
Despite significant efforts there is no consensus about the endogenous ligands for 
sigma receptors (Su et al., 1986; Contreras et al., 1987; Su & Vaupel, 1988; Zhang 
et al., 1988). Sigma receptors are localized in the brain, as well as, in many peripheral 
tissues including liver, spleen, and blood cells (Samoilova et al., 1988; Su et al.,
14
1988; Wolfe, S. A. et al., 1988; Wolfe, S. E. et al., 1989). In the brain, sigma 
receptors are mostly concentrated in the brainstem areas subserving motor functions 
(the red nucleus, cerebellum, substantia nigra pars compacta, and various cranial 
nerve nuclei: the facial, hypoglossal, and motor trigeminal nuclei) (Gundlach et a l, 
1986; McLean & Weber, 1988). However, the high densities of sigma receptors are 
also found in certain limbic structures, in the brain areas related to the regulation of 
sensory and endocrine function (McLean & Weber, 1988). Such location of sigma 
receptors may reflect their role in the regulation of a variety of physiological 
functions. However, it has been strongly established that sigma receptors are involved 
in the coordination of motor functions (Walker et a l, 1990). Indeed, the injection of 
several sigma agonists caused significant dystonia in rats (Matsumoto et a l, 1990).
Several antipsychotic drugs (haloperidol, chlorpromazine, remoxipride) interact 
with sigma receptors whereas the others (clozapine, raclopride, sulpiride) lack any 
activity on these receptors (Su, 1982; Largent et a l, 1984; Tam & Cook, 1984). 
Haloperidol is the most potent drug interacting with sigma receptors (Tam & Cook, 
1984; Itzhak, 1988). Recent behavioural, electrophysiological and receptor binding 
experiments provide evidence that haloperidol may act as a mixed agonist-antagonist 
of sigma receptors (Largent et a l, 1984; Bowen et a l, 1988; Tam et a l, 1988; 
Walker et a l, 1988; Beart et a l, 1989). The chronic administration of haloperidol 
considerably reduced the density of sigma receptors, but not their affinity in the rat 
brain (Itzhak & Alerhand, 1989; Kizu et a l, 1991; Jansen et a l, 1992).
2.2.4. Glutamate and NMDA-gated channels
Glutamate released from the fibers originating from the frontal cortex appears to be 
a major factor in the control of dopaminergic neurotransmission in the striatum and 
nucleus accumbens (Fonnum et al, 1981; Christie et a l, 1985). Moreover, dopamine 
receptors are located on the glutamatergic corticostriatal terminals, showing reciprocal 
interactions between dopamine and glutamate (Schwarcz, R. et a l, 1978; Roberts & 
Anderson, 1979; Nishikawa et a l, 1983). Therefore, antipsychotic drugs seem to 
affect the activity of the glutamatergic system. Moreover, clozapine displaces [3H]- 
MK-801, a non-competitive antagonist ofN-methyl-D-aspartate gated channels, from 
striatal homogenate (Lidsky et a l, 1993). Chlorpromazine also inhibits the binding 
of NMDA channel ligand [3H]-TCP to the rat brain membranes, but chronic 
administration of chlorpromazine does not change the density of NMDA channels in 
the rat cerebral cortex (Rehavi & Schnitzer, 1991). Clozapine efficiently blocks the 
stereotypies induced by dizocilpine. In the electrophysiological studies, clozapine 
suppresses electrical responses in the striatum evoked by the stimulation of 
glutamatergic corticostriatal pathways (Lidsky et a l, 1993). These data are 
apparently in favour of interaction of clozapine with glutamatergic neurotransmission.
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2.3. Sigma receptor antagonists as potential antipsychotic drugs
Interaction of several clinically potent antipsychotic drugs with sigma receptors led 
to the hypothesis that selective sigma receptor antagonists may possess antipsychotic 
activity. Limited clinical trials with rimcazole, a sigma receptor antagonist, have 
strengthened this idea. Rimcazole exhibited moderate antipsychotic activity in patients 
suffering from acute schizophrenic psychosis (Davidson et a l, 1982, 1985; Guy et 
a l , 1983; Chouinard & Annable, 1984; Schwarcz, G. A. et a l, 1985). Furthermore, 
the density of sigma receptors was markedly reduced in the temporal lobe of 
schizophrenic patients compared to age-matched controls (Weissman et a l, 1988, 
1991).
2.3.1. Biochemical effects
Several compounds display relatively higher affinity for sigma receptors than for any 
other known receptor types in the mammalian brain. The putative sigma receptor 
antagonists (haloperidol, cinuperone, BMY 14802, and rimcazole) inhibit [3H]-SKF 
10,047, an agonist of sigma receptors, binding to sigma receptors at lower 
concentrations than they inhibit its binding to NMDA-gated channels (Su et a l,
1988). Nevertheless, the interaction with other receptors should not be neglected if the 
action of these compounds is under the scope. Su (1986) established that cinuperone 
affected binding of radioligands to dopamine D2 and sigma receptors in the rat brain 
(Su, 1986). The enantiomers of BMY 14802 bind with approximately equal potency 
to 5-HT1A receptor (Taylor et a l, 1990).
Subchronic treatment with rimcazole increased the number of sigma binding sites 
in the rat brain (Manallack & Beart, 1988; Beart et a l, 1989), while haloperidol had 
the opposite action; reducing the density of sigma receptors (Itzhak & Alerhand,
1989).
Data of several studies suggest the modulation of dopaminergic activity by sigma 
receptors. First, using autoradiographic methods, sigma binding sites were detected 
on dopamine neurons of the rat (Gundlach etal, 1986) and cat (Graybiel e ta l,  1989) 
brain. Second, in electrophysiological and biochemical studies, sigma agonists and 
antagonists either increase or decrease the activity of dopamine neurons (Berkowitz, 
1974; Freeman & Bunney, 1984; Matthews et a l, 1986; Steinfels et a l, 1989; 
Iyengar et a l, 1990). The administration of sigma antagonists (BMY 14802, 
rimcazole and remoxipride) markedly accelerated dopamine turnover in the brain 
(Matthews et a l, 1986; Beart et a l, 1989; Iyengar et a l, 1990; Köhler et a l, 1990; 
Rao et a l, 1990; Gudelsky & Nash, 1992).
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2.3.2. Behavioural effects
The close interaction between sigma receptors and dopaminergic system determines 
the effectiveness of sigma antagonists in the behavioural tests used to reveal the 
potential antipsychotic activity of drugs. Rimcazole was identified as a potential 
antipsychotic drug in the behavioural experiments potently antagonizing 
apomorphine-induced behaviours in rodents (Ferris et a l , 1982). Rimcazole was 
effective against apomorphine-induced aggressiveness in rats, and apomorphine- 
induced climbing behaviour in mice, but did not affect apomorphine-induced 
stereotyped gnawing (Ferris et a l, 1982). Furthermore, rimcazole displayed very 
limited activity at dopamine receptors in the radioligand binding studies whereas it 
efficiently blocked sigma receptors (Ferris et a l , 1986a, b). Cinuperone displayed a 
very similar behavioural profile to rimcazole (Hock et a l, 1985)). The subsequent 
radioligand binding studies also excluded the role of dopamine in the action of 
cinuperone (Su, 1986). Remoxipride was more potent to inhibit apomorphine-induced 
stereotyped behaviour than to induce catalepsy in the rat (Florvall & Ögren, 1982). 
Moreover, remoxipride displayed higher selectivity against apomorphine-induced 
hyperlocomotion compared to stereotypies elicited by dopamine agonists (Ögren et 
a l,  1984). The sigma antagonist BMY 14802 did not cause catalepsy at any dose 
administered and it reversed catalepsy produced by haloperidol (Matthews et a l,
1986). Accordingly, the above described sigma antagonists resemble, in many 
respects, the atypical antipsychotic drugs.
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3. AIMS OF THE PRESENT STUDY
As discussed above, not only dopamine D2 receptors, but also several other receptors, 
are involved in the action of antipsychotic drugs and the pathophysiology of 
schizophrenia. According to current understanding the most concerned receptors are 
5-HT2a and 5-HT2C, dopamine D, and sigma receptors, and also NMDA-gated 
channels. Moreover, it has been hypothesized that effective antipsychotic treatment 
with the reduced liability of EPS requires blockade of two or more receptor systems 
in the brain (Kahn & Davidson, 1993; Seeman & Van Tol, 1994). Taking into 
account the complicated nature of the antipsychotic action of various drugs, the main 
aims of the present study were as follows:
1) To compare the typical and atypical antipsychotic drugs by means of receptor 
binding studies and animal models reflecting the possible antipsychotic potency of 
drugs. Special attention was paid to the interaction of these drugs with dopamine, 
sigma, 5-HT2A receptors, and NMDA-gated channels.
2) To study the role of sigma receptors in the action of antipsychotic drugs. Selective 
sigma antagonists were compared with the antipsychotic drugs in acute and long-term 
experiments using radioligand binding and behavioural studies.
3) The current practice to reveal antipsychotic drugs utilizes a disease-like state 
induced by acute drug treatments. However, schizophrenia and other psychotic states 
are chronic and highly devastating diseases. Therefore, the use of subchronic animal 
models was considered to be important. For that purpose we used the aggressive 
behaviour induced by repeated apomorphine treatment. Two major questions were 
addressed. First, to examine the selectivity of this model to reveal the antipsychotic 
activity of drugs. Second, special attention was paid to the role of NMDA-gated 
channels in the development of aggressive behaviour.
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4. MATERIALS AND METHODS
4.1. Animals
Male Wistar rats (Kuo:WIST) and (Rap: WIST) were supplied by the National Animal 
Center, Kuopio, Finland and Rappolovo Farm of Laboratory Animals, Russia, 
respectively. The source of male albino mice was the Rappolovo Farm of Laboratory 
Animals, Russia. Rats weighing 180-300 g were housed in groups of five. Mice 
weighing 25-30 g were housed in groups of 15-25. Animals were kept under 
standard laboratoiy conditions (temperature 20±3°C) with free access to tap water 
and pelleted rat/mouse feed (STS, UK). An artificial 12 h light-dark cycle was used 
(lights on at 8:00).
4.2. Drugs
The commercial solution of haloperidol (Gedeon Richter, Hungary) was diluted in 
saline immediately before the experiment. Raclopride: (-)(S)-3,5-dichloro-N[(l-ethyl- 
2-pyrrolidinyl)methyl]-6-methoxysalicylamide tartrate (Astra AB, Sweden), 
chlorpromazine (Sigma, USA), remoxipride: (S)(-)-3-bromo-2,6-dimethoxy-N-[(l- 
ethyl-2-pyrrolidinyl)methyl]-benzamide (Astra AB, Sweden), BMY 14802: a-(4- 
fluorophenyl)-4-(-flouro-2-pyrimidinyl)-l-piperazine butanol (Bristol-Myers & 
Squibb, USA), apomorphine hydrochloride (Sigma, USA), d-amphetamine (Sigma, 
USA), quipazine dimaleate (Research Biochemicals International, USA), dizocilpine 
maleate: (+)-5-methyl-10,1 l-dihydro-5-H-dibenzo[a,d]cycloheptan-5,10-imine 
maleate (Merck Sharp & Dohme, UK) and rimcazole: (cis-9-[3-3,5-dimethyl-l- 
piperazinyl)propyl]carbazole dihydrochloride (Burroughs-Wellcome, USA) were 
dissolved in saline. Clozapine (Sandoz, Switzerland) and cinuperone: 3-(4-(3-(4- 
fluorobenzoyl)-propyl-piperazino-l-yl)-isoquinolino-hydrochloride (Hoechst, 
Germany) were suspended in the saline with the help of 1 -2 drops of Tween-85. SCH 
23390: R(+)-7-chloro-8-hydroxy- 1-phenyl-2,3,4,5-tetrahydro- lH-3-benzazepine 
hydrochloride (Research Biochemicals International, USA) was dissolved in 0.1% 
ascorbic acid.
4.3. Radioligand binding studies
The radioligand binding studies included two sets of experiments. In in vitro studies 
the IC50 values of respective drugs were determined. In the case of subchronic 
treatment of drugs the affinity and the capacity of binding sites were detected.
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4.3.1. Preparation of brain samples for radioligand binding studies
For in vitro binding studies the membranes prepared from various structures of the 
rat brain were used. Animals were killed by decapitation. The brains were rapidly 
removed from the skull and the brain structures were dissected on ice. The brain 
structures were stored at -20°C until the following procedures. Brain tissues were 
thawed on the day of experiment and were homogenized with a Potter-S homogenizer 
(1000 rpm, 12 passes) in 20 vol ice-cold 50 mM Tris-HCl buffer (pH 7.4 or 7.7 in the 
case of pHj-spiperone, [^-haloperidol, [3H]-SCH 23390, [3H]-ketanserin, [3H]-MK- 
801 or [3H]-TCP, respectively). Membranes were washed twice by centrifugation at 
48000 x g for 15 min. After the last centrifugation the tissues were suspended in 
incubation buffer for the appropriate binding assay.
4.3.2. [3H]-Spiperone binding (I, II, III; dopamine D2 receptors)
[3H]-Spiperone (specific activity 109 Ci/mmol, Amersham, UK, final concentrations 
0.06-2 nM to create saturation curves or 0.1 nM to measure IC50 values of drugs) was 
incubated 30 min at 37°C with the membrane preparation (1 mg wet weight/tube) in
0.5 ml of incubation buffer consisting of Tris-HCl 50 mM, NaCl 120 mM, KC1 
5 mM, CaCl2 2 mM, MgCl2 1 mM (pH 7.4). Nonspecific binding was determined in 
the presence of raclopride. The reaction was stopped by rapid centrifugation at 11000 
x g for 4 min.
4.3.3. [3H]-Haloperidol binding (I, II; sigma receptors)
The rat brain homogenates (12 mg wet weight/tube) were incubated with increasing 
concentrations (2.5-80 nM for saturation studies) or 1.7 nM (to detect IC50 values for 
different drugs) of [3H]-haloperidol (specific activity 8.9 Ci/mmol, Dupont-NEN, 
USA) in the absence and presence of 10 цМ haloperidol to determine specific 
binding. Spiperone (50 nM) was added to each tube to block [3H]-haloperidol binding 
to dopamine D 2, 5-HT2, a, adrenergic receptors. This approach was used since 
spiperone was inactive at sigma binding up to low micromolar concentrations. The 
incubation was carried out in the total volume of 1 ml 50 mM Tris-HCl buffer (pH 
7.7). After a 90-min incubation at room temperature the membrane-bound [3H]- 
haloperidol was separated from free radioligand by rapid filtration through Whatman 
GF/B glass fibre filters (presoaked with 0.05% polyethyleneimine) using a Brandel 
Cell Harvester (MS-24S, USA). After filtration the filters were washed twice (4.5 ml 
each) with incubation buffer.
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4.3.4. [3H]-TCP binding (I; NMDA-gated channels)
NMDA-gated channels were measured by means of using 7.5 or 2 nM [3H]-TCP 
(specific activity 60 Ci/mmol, Dupont-NEN, USA) in the presence of 2-100 nM of 
dizocilpine (IC50 studies). The incubation of brain membranes (12 mg wet 
weight/tube) was carried out in the total volume of 0.5 ml 5 mM Tris-HCl buffer (pH 
8.1 at 20°C) for 45 min at room temperature. The incubation was terminated by rapid 
filtration as described above.
4.3.5. [3H]-Ketanserin binding (II; 5-HT2 receptors)
Binding of [3H]-ketanserin (specific activity 72.3 Ci/mmol, Dupont-NEN, USA, 
1 nM) to the frontal cortex membranes (2 mg wet weight/tube) was performed in the 
total volume of 1 ml 50 mM Tris-HCl buffer (pH 7.4) at room temperature. To detect 
nonspecific binding unlabelled ketanserin (10 цМ) was added. After 30 min the 
incubation was stopped as described earlier with [3H]-haloperidol binding.
4.3.6. [3H]-SCH-23390 binding (II; dopamine D l receptors)
The incubation of the rat striatal membranes (1 mg wet weight/tube) was carried out 
in 0.5 ml of incubation buffer (Tris-HCl, 50 mM, pH 7.4) during 45 min with [3H]- 
SCH-23390 (specific activity 85 Ci/mmol, Amersham, UK, 2 nM) at room 
temperature. Nonspecific binding was detected in the presence of 10 цМ SCH-23390. 
The reaction was stopped by rapid centrifugation at 11000 x g for 4 min.
4.3.7. [3H]-MK-801 binding (III; NMDA-gated channels)
[3H]-MK-801 (specific activity 25 Ci/mmol, Dupont-NEN, USA, 1-80 nM) was 
incubated with the homogenized membranes in Tris-HCl buffer (50 mM) at room 
temperature in total incubation volume of 0.5 ml. In order to detect nonspecific 
binding 100 цМ of unlabelled MK-801 (dizocilpine) was used. The incubation was 
terminated after 60 min by rapid filtration over Whatman GF/B filters. The filters 
were washed with 10 ml cold incubation buffer.
The radioactivity of samples was measured by means of liquid scintillation 
spectrometry at 50 per cent efficiency level. Saturation curves were processed by 
means of non-linear least squares regression analysis (Leatherbarrow, 1987). The 
protein content (III) was measured according to a modification of the Lowry procedure 
(Markwell et al., 1978).
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The IC50 values for antipsychotic drugs and sigma antagonists were detected 
using the methods described above. Always 10-12 concentrations of test compounds 
were used to inhibit [3H]-ligand binding. These experiments were repeated at least 4 
times.
4.4. Behavioural experiments
4.4.1. Apomorphine-induced yawning in rats (I, II)
The behavioural testing was performed as described by Morelli et al. (1986). The 
number of yawns was counted during 1 h after subcutaneous (s.c.) treatment with 
apomorphine (0.1 mg/kg). Sigma antagonists and antipsychotic compounds were 
injected intraperitoneally (i.p.) 30 min before the administration of apomorphine.
4.4.2. Apomorphine-induced climbing in mice (I, II)
The climbing behaviour was studied according to the method of Moore and Axton 
(1988): apomorphine (3 mg/kg, s.c.) and test compounds were injected 5 min and 
30 min respectively before the placement of animals into individual wire net cages 
where the climbing activity was observed over 30 min.
4.4.3. Amphetamine- and dizocilpine-induced motor excitation in 
mice (1, II)
Locomotor activity was measured in individual cylindrical cages (diameter 40 cm), 
with 2 photocells located in the wall (Vasar et al., 1990). Locomotor activity was 
counted between 15 and 45 min after administration of d-amphetamine (5 mg/kg, s.c.) 
or dizocilpine (0.25 mg/kg, i.p ). The test compounds were injected 30 min before the 
measurement of motor activity.
4.4.4. Apomorphine-induced stereotyped behaviour in rats (I, II)
Apomorphine (0.5 mg/kg, s.c.) was injected 30 min and the test drugs 60 min prior 
to the registration of stereotyped behaviour according to the scale of Costall and 
Naylor (Costall & Naylor, 1974). Stereotyped behaviour was measured 
simultaneously with the aggressive behaviour.
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4.4.5. Apomorphine-induced aggressiveness in rats (I, II, III)
The animals were sensitized to apomorphine aggressiveness by 10 days of repeated 
treatment with apomorphine (0.5 mg/kg twice daily, s.c.) (Allikmets & Vasar, 1982). 
Aggressiveness was studied in the grouped rats (8-10 rats together in the test cage). 
Aggressive behaviour was measured in a cage (the walls of the cage were made of 
glass) 55x40x40 cm. Apomorphine-induced (0.5 mg/kg, s.c.) aggressiveness was 
assessed in a 5-minute observation period at the end of each 15-minute monitoring 
period Rating of aggressive behaviour was performed on a 0-4 point scale described 
by Allikmets et al. (1979). The number of rats showing apomorphine-induced 
aggressive behaviour (aggressive posturing, boxing, biting, vocalization etc.) was 
registered. All the drugs under the study were injected i.p. 30 min before treatment 
with apomorphine.
4.4.6. Quipazine-induced head twitches (II)
Head twitches were induced by quipazine, an agonist of 5-HT receptors (Vetulani et 
al., 1980). The number of head twitches was observed during 30 min after the 
administration of quipazine (2.5 mg/kg, i.p ). The studied compounds were injected
i.p. 30 min before treatment with quipazine.
4.4.7. Behavioural studies after chronic treatment (I)
Haloperidol (0.5 mg/kg daily, i.p ), clozapine (10 mg/kg daily, i.p.) and BMY 14802 
(10 mg/kg daily, i.p.) were administered to the rats for 15 days. Dizocilpine-induced 
behaviour was investigated 72 h after the last injection of test drugs. Dizocilpine 
(0.2 mg/kg) was administered s.c. 30 min prior to the registration of stereotyped 
behaviour according to the scale of Costall and Naylor (Costall & Naylor, 1974). 
After that the animals were placed into an open field ( lxl  x0.4 m). The numbers of 
line crossings and rearings during 5 min was counted. The intensity of ataxia was 
measured according to the method of Contreras et al. (1986).
Apomorphine-induced behavioural effects were also measured 72 h after the last 
injection of haloperidol, clozapine and BMY 14802. Apomorphine (0.15 mg/kg) was 
injected s.c. 15 min prior to the experiment. The intensity of stereotyped gnawing 
(Costall & Naylor, 1974), the numbers of line crossings, rearings, and head-dippings 
in the open field were registered.
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4.5 Statistical analysis
In binding studies the mean apparent equilibrium dissociation constants (KD) and 
maximum number of binding sites (Bma*) were calculated using the nonlinear iterative 
curve-fitting program (Enzfitter) of Leatherbarrow (Leatherbarrow, 1987). The 
remainder of statistical data analyses were calculated by using Statistica for Windows 
(StatSoft Inc., USA) and Pharmacological Calculation System (Tallarida & Murray,
1986) statistical software. Log-plot analysis was applied to determine IC50 values for 
test compounds.
In behavioural studies the ED50 values for all drugs were calculated from log 
dose-response curves. However, in the case of apomorphine-induced stereotypy and 
aggressiveness, the dose of drug was detected completely blocking the behavioural 
effects of apomorphine.
The mean values ± S.E.M. are presented in tables and figures. Mann-Whitney 
U-test was used to evaluate the significance of behavioural effects of drugs. One-way 
analysis of variance (ANOVA) followed by Duncan's multiple range test or Student's 
t-test (if two mean values were compared) were used for evaluation of the radioligand 
binding data.
The Pearson correlation analysis was employed to reveal the relations between 
the behavioural and radioligand binding data.
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5. RESULTS 
5.1. In vitro receptor binding studies
In the radioligand binding studies the antipsychotic compounds and sigma antagonists 
were tested to inhibit specific radioligand binding to different receptor types to find 
the IC50 values for them. These results are presented in Table 2.
T a b l e  2
Inhibition of in vitro radioligand binding by test compounds
Radioligand 
Receptor type 
Structure
Drug
PH]-
Spiperone 
Dopamine D2 
Striatum
[Щ- 
SCH 23390 
Dopamine D, 
Striatum and 
mesolimbic 
area
№
Haloperidol
Sigma
Cerebellum
[3H]-
Ketanserin
5-НТ2Д/2С
Frontal cortex
Haloperidol 5.5±0.8 350±59 1.2±0.4 200±18
Raclopride 8.9±1.1 >100000 >10000 9800±910
Chlorpromazine 16±2.9 400±60 180±11 67±4.2
Clozapine 300±25 210±42 >10000 28±1.3
Remoxipride 1400±110 >100000 110±11 15000±1400
Cinuperone 76±13 6200±550 32±3.3 240±28
BMY 14802 5100±420 44000±5600 83±9.1 15000±2200
Rimcazole 5200±530 15000±2500 280±24 2300±290
SCH 23390 1700±150 0.93±0.1 >10000 19=Ы .2
Results are presented as IC50 values in nM.
All tested antipsychotic drugs exerted notable affinity for dopamine D2 receptors 
labeled with [3H]-spiperone. Haloperidol and raclopride were the most potent 
inhibitors of [3H]-spiperone binding to dopamine D2 receptors, reducing it at a low 
nanomolar level. Other antipsychotic drugs such as chlorpromazine and especially 
clozapine were less effective inhibitors of [3H]-spiperone binding in the striatum. By 
variance from antipsychotic compounds the IC50 values of sigma antagonists
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(remoxipride, BMY 14802 and rimcazole) against [3H]-spiperone binding were in 
micromolar range. Cinuperone was an exception among sigma antagonists, being a 
potent inhibitor of [3H]-spiperone binding (IC50-76 nM) to dopamine D2 receptors.
Antipsychotic drugs like haloperidol, chlorpromazine, and clozapine displayed 
moderate affinity for dopamine D, receptors, whereas raclopride was unable to 
interact with this type of receptor (Table 2). High concentrations of cinuperone, BMY 
14802, remoxipride and rimcazole (>10 цМ) were needed to inhibit [3H]-SCH 23390 
binding to dopamine D, receptors. The most effective blocker of [3H]-SCH 23390 
binding was the selective dopamine D, antagonist SCH 23390. Majority of tested 
compounds (haloperidol, chlorpromazine, remoxipride, cinuperone, BMY 14802, 
rimcazole) were more effective at dopamine D2 than at dopamine D, receptors. The 
only exception was an atypical antipsychotic drug clozapine that had nearly similar 
affinity for both dopamine receptors.
Studying drug potencies at sigma receptors showed the inability of clozapine, 
raclopride and SCH 23390 to inhibit specific binding of [3H]-haloperidol to sigma 
receptors in the cerebellum up to the concentration of 10 цМ, while all the other tested 
compounds had IC50 values less than 300 nM (Table 2). Again, haloperidol was by 
far the most potent antagonist of [3H]-haloperidol binding to sigma receptors in the 
rat cerebellum. Remoxipride, BMY 14802, rimcazole and cinuperone were apparently 
more potent at sigma receptors compared to the other receptors studied.
Chlorpromazine, clozapine and SCH 23390 displayed significant affinity for 5- 
HT2 receptors labeled with [3H]-ketanserin (Table 2). Haloperidol and cinuperone 
exerted only moderate activity at these 5-HT-receptors. Very high concentrations of 
other compounds were needed to inhibit [3H]-ketanserin binding.
All studied compounds (up to 100 цМ) were ineffective against [3H]-TCP and 
[3H]-MK-801 binding in the rat frontal cortex.
5.2. Results of acute beha vioural experiments (I, II)
5.2.1. Antipsychotic drugs (I, II)
In acute behavioural studies the antipsychotic compounds and sigma antagonists were 
tested to inhibit different drug-induced behaviours to find the ED50 values for them. 
These results are presented in Table 3.
The studied antipsychotic drugs inhibited drug-induced behaviour in the following 
order of potency: haloperidol > raclopride > chlorpromazine  ^ clozapine. It is worthy 
to note that clozapine was a relatively more effective antagonist of dizocilpine- 
induced motor excitation as compared to its action against amphetamine-induced 
locomotor stimulation. This behavioural profile differed from the other studied 
antipsychotics.
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T a b l e  3
Inhibition of drug-induced behaviour
Drug
Apomorphine-
induced
stereotypy
Apomorphine-
induced
aggressiveness
Apomorphine- 
induced climbing
Apomorphine- 
induced yawning
Amphetamine-
induced
hypermotility
Dizocilpine-
induced
hypermotility
Quipazme- 
induced head 
twitches
Haloperidol 0.67 0.67 0.35 0.13 0.37 0.43 0.27
(0.22-1.3) (0.08-0.36) (0.26-0.70) (0.27-0.56) (0.15-0.67)
Raclopride 2 1 1 0.34 1.6 1.6 2.1
(0.80-1.5) (0.18-0.67) (0.61-3.0) (0.32-3.0) (0.11-32)
Chlorpromazine 28 28 5.6 3.9 3.7 3.4 3.8
(2.5-14) (0.56-6.5) (1.9-5.9) (0.70-7.3) (0.98-15.0)
Clozapine >31 31 24 3.4 17 6.4 1.9
(8.3-46) (1.1-8.0) (10-29) (3.4-12) (0.24-15)
Remoxipride 24 12 4.7 1.7 4.2 5.2 15
(1.4-16) (0.29-3.3) (1.4-8.0) (2.1-12) (3.8-57)
Cinuperone >51 >51 10 15 4 2.2 0.97
(2.1-63) (1.8-32) (0.60-6.5) (1.4-5.6) (0.18-5.3)
BMY 14802 >115 >115 45 7.5 30 27 15
(20-67) (1.5-14) (16-50) (7.8-68) (9.7-23)
Rimcazole >127 >127 127 60 48 70 >102
(34-150) (35-61) (18-71) (32-120)
SCH 23390 2.5 0.62 0.052 >2.5 0.097 0.66 0.04
(0.019-0.15) (0.06-0.16) (0.10-4.2) (0.0057-0.27)
Results are ED50 values and confidence limits (in brackets) for them in /umol/kg. In case of apomorphine-induced stereotypy and aggressiveness doses 
completely blocking these behavioural effects of apomorphine are given.
Both typical and atypical antipsychotic drugs effectively antagonized the 
manifestation of aggressive behaviour (Table 3). The atypical antipsychotic drug 
clozapine did not block the apomorphine-induced stereotypies. At high doses 
(>31 nmol/kg) clozapine even increased the intensity of apomorphine-induced 
gnawing. Raclopride also displayed higher effectiveness against apomorphine-induced 
aggressiveness and amphetamine-induced hyperlocomotion compared to its action 
against apomorphine-induced stereotyped behaviour.
The selective dopamine D, receptor antagonist SCH 23390 was effective in most 
behavioural tests at very low doses. However, much higher doses, inducing very 
significant catalepsy, were required to block apomorphine-induced aggressiveness and 
stereotyped behaviour.
5.2.2. Sigma receptor antagonists (I, II)
Overall, markedly higher doses of sigma antagonists (cinuperone, BMY 14802, and 
rimcazole) were needed to antagonize the behavioural effects of apomorphine, 
amphetamine, and quipazine, compared to antipsychotic drugs (Table 3). 
Furthermore, the preferential sigma antagonists (cinuperone, BMY 14802 and 
rimcazole) did not antagonize apomorphine-induced stereotypy and aggressiveness 
in the rat at all. Rimcazole did not block quipazine-induced head twitches either. In 
a majority of behavioural tests remoxipride was the most potent among the sigma 
antagonists, but in case of dizocilpine-induced hyperlocomotion and quipazine- 
induced head twitches cinuperone was more active compared to remoxipride.
5.2.3. Correlations between radioligand binding data and 
behavioural effects
Pearson correlation coefficients, calculated between the potencies of all studied 
compounds in behavioural tests, revealed very good correlation between different 
behavioural tests (r=0.7286-0.9969). The ED50 values of tested antipsychotics and 
sigma antagonists in the behavioural experiments correlated extremely well with their 
ICjo values at dopamine D2 receptors (r=0.6526-0.8732), but not with their affinities 
at dopamine D,, 5-HT2A/2C and sigma receptors (r<0.48).
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5.3. Subchronic administration of antipsychotic drugs and sigma 
antagonists (I)
5.3.1. Results of radioligand binding (I)
Results of effects of subchronic treatment with haloperidol, clozapine and BMY 
14802 on brain receptor binding parameters are presented in Table 4.
T a b l e  4
Effect of subchronic treatment with haloperidol, clozapine and BMY 14802 on 
dopamine D2, NMDA-gated channels and sigma receptors
Subchronic treatment
Receptor type Structure
Saline Haloperidol Clozapine BMY
14802
Dopamine D2 
receptors
Striatum Bmax
k d
22.8±1.2
0.17±0.001
35.4±3.8*
0.45±0.Г
27.4±2.0
0.23±0.06
25.4±2.1 
0.19±0.05
Mesolimbic
area
Bmax
k d
7.5±0.8
0.08±0.01
13.1±1.7*
0.38±0.11*
9.6±0.6
0.14±0.02*
9.6±1.0
0.12±0.04
NMDA-gated
channels
Frontal cortex Bmax
k d
115±8 
7.0±1.5
120±10
5.2±1.2
152±12*
6.5±0.6
110±12
10.U1.6
Hippocampus Bmax
k d
142±13
10.1±1.4
143±14
9.8±1.6
165±15
10.8±1.2
153±14
12.7±1
Sigma
receptors
Frontal cortex Bmax
k d
336±20
7.8±0.8
367±18
16.4±2.0‘
345±30
10.4±1.0
450±30*
13.4±1.0*
Cerebellum Bmax
k d
415±34
16.4±2.0
206±22*
10±1.2
344±30
12.8±1.0
456±32
16.2±1.6
Bmax values are presented in finol/mg of wet weight tissue; KD values are in nM. * P < 0.05 
compared to saline treated animals.
Repeated treatment with haloperidol significantly increased the number and reduced 
the affinity of dopamine D2 receptors in the striatum and mesolimbic area. The 
affinity of dopamine D2 receptors labelled by [3H]-spiperone in the mesolimbic 
structures was also decreased to some extent after long-term treatment with clozapine. 
The elevation of density of dopamine D2 receptors in the subcortical structures,
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induced by repeated administration of clozapine and BMY 14802, was not 
statistically significant.
Only the long-term administration of clozapine, an atypical antipsychotic drug, 
increased the density of [3H]-TCP binding sites in the rat frontal cortex, whereas 
BMY 14802 and haloperidol were ineffective.
Repeated treatment with BMY 14802, a selective sigma receptor antagonist, 
increased the density and reduced the affinity of [3H]-haloperidol-labelled sigma 
receptors in the frontal cortex. By contrast, subchronic treatment with haloperidol, as 
with BMY 14802, decreased the affinity of sigma sites in the frontal cortex, but 
unlike the sigma antagonist, it decreased nearly 50% the density of sigma receptors 
in the cerebellum. Repeated treatment with clozapine did not cause any noticeable 
changes in [3H]-haloperidol binding at sigma receptors.
5.3.2. Results of behavioural experiments (I)
The administration of dizocilpine at a dose of 0.2 mg/kg induced the stereotyped 
behaviour like sniffing, head movements, circling behaviour and ataxia, but never 
gnawing stereotypies in the rat. Simultaneously, dizocilpine increased the number of 
line crossings but decreased the number of rearings in the open field test. Repeated 
treatment (15 days) with haloperidol (0.5 mg/kg daily), clozapine (10 mg/kg daily) 
and BMY 14802 (10 mg/kg daily) did not change stereotyped sniffing and ataxia 
induced by dizocilpine. Repeated treatment with clozapine significantly enhanced the 
effect of dizocilpine on line crossings and nearly restored the number of rearings 
suppressed by NMDA-gated channel non-competitive antagonist. Long-term 
treatment with haloperidol and BMY 14802 also increased to some extent the 
locomotor effect of MK-801 but this increase was statistically insignificant.
The administration of unselective dopamine agonist apomorphine (0.15 mg/kg) 
induced syndrome of stereotyped gnawing and significantly inhibited motor activity 
in rats treated with saline. Apomorphine decreased the numbers of line crossings, 
rearings and head-dips in the open field test. Chronic pretreatment with clozapine and 
BMY 14802 antagonized completely motor depressant effect of low dose of 
apomorphine. Long-term treatment with clozapine differently from that of haloperidol 
and BMY 14802 reduced intensity of stereotyped behaviour in the rat. The subchronic 
treatment with haloperidol also attenuated, to some extent, the motor depressant effect 
of apomorphine but only antagonism with the decreased number of head-dips was 
statistically significant.
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5.4. Apomorphine-induced aggressiveness (III)
The first injection of apomorphine (0.5 mg/kg) caused a set of behavioural effects 
characterized by repeated sniffing, licking, and gnawing. Repeated administration of 
apomorphine made animals irritable on the third day of treatment: rats presented 
sudden bursts of locomotor activity in response to noise or the approach of another 
rat. Some rats displayed also the upright threatening posture, sham boxing and 
vocalization. The intensity of aggressive behaviour became gradually stronger during 
the course of repeated injections with apomorphine. All rats became aggressive by the 
seventh day of treatment. Increasingly vigorous tail-vibration and short bursts of 
locomotion always preceded this behavioural syndrome of aggressive behaviour. 
These behavioural manifestations occurred later after each injection of apomorphine. 
Aggressive behaviour became longer (it lasted about 45 min on the 10th day of 
treatment) during the course of repeated injections with apomorphine. Syndrome of 
apomorphine-induced aggressive behaviour was very steady. Once induced, any 
subsequent injection of apomorphine resulted in a similar behaviour. Administration 
of apomorphine even 3 months after the last injection of 10-day medication induced 
aggressive behaviour.
Neither density nor affinity of dopamine D2 receptors labelled by [3H]-spiperone 
was changed in the striatum after a single or a repeated treatment of rats with 
apomorphine (0.5 mg/kg). Ten-day apomorphine treatment significantly increased the 
number of [3H]-MK-801 binding sites in the frontal cortex and hippocampus, but not 
in the striatum. The challenging of previously sensitized rats to apomorphine 
(0.5 mg/kg) almost normalized the density of [3H]-MK-801 binding sites in the 
frontal cortex. However, in the hippocampus, parameters of [3H]-MK-801 binding 
sites remained unchanged after the challenge dose of apomorphine.
Effects of antipsychotic drugs and sigma antagonists against apomorphine- 
induced aggressiveness were described in earlier parts (5.2.1. and 5.2.2).
A single injection of dizocilpine, a non-competitive NMDA-gated channel 
antagonist, did not affect stereotyped behaviour in rats sensitized to apomorphine. 
Administration of dizocilpine at doses above 0.25 mg/kg blocked signs of aggressive 
behaviour caused by apomorphine. However, this effect of dizocilpine was 
accompanied by a marked impairment of muscular coordination, starting at
0.25 mg/kg and worsening at 0.5 mg/kg.
The coadministration (twice daily for 10 days) of dizocilpine (0.25 mg/kg) with 
apomorphine (0.5 mg/kg) completely blocked the development of aggressive 
behaviour. However, the lowest dose of dizocilpine (0.025 mg/kg) even accelerated 
the onset of aggressive behaviour — all rats became aggressive already on the third 
day of treatments.
After completing the experiments where the aggression-blocking dose of 
dizocilpine (0.25 mg/kg) and apomorphine (0.5 mg/kg) were injected together the 
action of apomorphine was studied. The first injection of apomorphine did not induce
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any signs of aggressive behaviour in these rats. The response of these rats to repeated 
treatment with apomorphine did not differ from that of saline-treated animals. Only 
on the third day of apomorphine administration were the first signs of aggressiveness 
evident. The administration of dizocilpine (0.25-1 mg/kg daily for 7 days) to rats 
sensitized to apomorphine did not affect the increased sensitivity of rats to 
apomorphine-induced aggressiveness.
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6. DISCUSSION
6.1. Profile of tested compounds in radioligand binding studies
In radioligand binding studies performed in vitro, the tested compounds had rather 
different profiles. Haloperidol, chlorpromazine and raclopride displayed high affinity 
for dopamine D2 receptors. Haloperidol was the most potent inhibitor of [3H]- 
spiperone binding to dopamine D2 receptors, whereas raclopride displayed the highest 
selectivity for these receptors. Differently from the other dopamine antagonists 
haloperidol had very high affinity for sigma receptors. The second important target 
for the action of chlorpromazine was 5-HT2A/2C receptor. The interaction with 5- 
НТгдяе receptors was dominating in the action of clozapine. SCH 23390 was by far 
the most potent compound to inhibit radioligand binding to dopamine D, receptors. 
None of the tested antipsychotic drugs interacted with NMDA-gated channels labelled 
by [3H]-TCP or [3H]-MK-801. Therefore, the interaction with dopamine and 5- 
hydroxytryptamine receptors should be considered when the antipsychotic action of 
drugs is under the scope. This statement is in good agreement with the recent studies 
of Leysen et al. (1993).
The sigma antagonists (remoxipride, cinuperone, BMY 14802, rimcazole) 
displayed the highest affinity for sigma receptors compared to other receptors studied. 
The affinity of these compounds for dopamine and 5-HT receptors was very variable 
but it was always lower than their efficacy at sigma receptors. In conclusion, the 
radioligand binding studies revealed the interaction of antipsychotic drugs with 
dopamine D,, dopamine D2,5-HT2A/2C and sigma receptors.
6.2. Comparison of typical and atypical antipsychotic drugs in 
acute and subchronic studies
A substantial amount of data are in favour of significant difference in the behavioural 
action of atypical and typical antipsychotic drugs (Costall & Naylor, 1975; Simon & 
Puech, 1979; Worms et al., 1983). As a rule, the atypical drugs do not block 
apomorphine-induced stereotyped behaviour or significantly higher doses are required 
compared to their action in the other behavioural tests. The cataleptogenic potency of 
atypical compounds is very weak or missing (Costall & Naylor, 1975; Janssen & Van 
Bever, 1978; Niemegeers & Janssen, 1979; Worms & Lloyd, 1979).
Haloperidol, a widely used, typical antipsychotic drug, was not only a potent 
inhibitor of dopamine D2 receptor binding, but it also had the most prominent action 
in behavioural studies. Haloperidol displayed nearly equal efficacy in all behavioural 
tests performed. It is worth noting that haloperidol antagonized apomorphine-induced 
aggressiveness only in doses blocking the stereotyped behaviour. As a matter of fact, 
identical doses of haloperidol induced marked catalepsy in rats. However, the
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relevance of sigma receptors in the action of haloperidol should also be taken into 
account due to its high affinity for these binding sites.
Another typical antipsychotic drug, chlorpromazine, exerted a behavioural pattern 
similar to haloperidol but at substantially higher doses. The action of chlorpromazine 
was particularly weak against apomorphine-induced aggressiveness. The 
antiaggressive action of chlorpromazine was accompanied, like in case of haloperidol, 
with significant catalepsy and a blockade of stereotyped behaviour. The different 
effectiveness of haloperidol and chlorpromazine against apomorphine-induced 
aggressiveness is in good correlation with their clinical potency (Seeman et al., 1976).
The behavioural profile of raclopride differed from that of haloperidol and 
chlorpromazine. Raclopride was weak in inducing catalepsy (Hillegaart & Ahlenius,
1987) and it was less effective to inhibit quipazine-induced head-twitches and 
apomorphine-induced stereotyped behaviour. The reduced effectiveness of raclopride 
against quipazine-induced head-twitches could be explained in light of the negligible 
affinity of raclopride for 5-HT receptors mediating this particular behaviour (Yocca 
et a l 1991). The weaker potency of raclopride against apomorphine-induced 
stereotyped behaviour compared to the antagonism of raclopride with apomorphine- 
induced aggressiveness is linked to the regional selectivity of drug toward the 
mesolimbic dopaminergic system (Hillegaart & Ahlenius, 1987). Consequently, our 
data are in favour of the proposed idea that raclopride belongs to the atypical 
antipsychotic drugs (Hillegaart & Ahlenius, 1987).
Clozapine, another antipsychotic drug with atypical action, was the most effective 
drug against quipazine-induced head-twitches. This is in good accordance with the 
radioligand binding data since in the present study clozapine displayed the highest 
effectiveness against the binding of pH]-ketanserin to S -H T ^c receptors. Clozapine 
did not prevent the stereotyped behaviour induced by apomorphine. Moreover, it even 
tended to increase the intensity of gnawing syndrome. The potentiation of stereotyped 
behaviour by clozapine differentiates it from other antipsychotic drugs. However, this 
effect of clozapine occurred at doses remarkably higher than required to inhibit other 
apomorphine-induced behaviours. Clozapine rather selectively antagonized 
dizocilpine, a non-competitive antagonist of NMDA-gated channels, induced 
hyperlocomotion in mice. This is in line with the existing data that clozapine is a 
potent antagonist of dizocilpine-induced behaviours in rodents (Tiedtke et a l, 1990). 
In some studies the interaction of clozapine with NMDA-gated channels has been 
established even in the radioligand binding studies (Janowsky & Berger, 1989). 
However, in the present study clozapine did not affect binding of [3H]-TCP to 
NMDA-gated channels in in vitro studies at all. However, it could be possible that 
clozapine affects NMDA-gated channels indirectly via the noradrenergic mechanisms 
in the brain (Rao et a l 1991). Therefore, two major conclusions can be drawn about 
the action of clozapine. First, clozapine obviously discriminates the dopaminergic 
systems in the distinct brain structures. Clozapine increased the dopaminergic activity 
in the striatum (increase of stereotyped behaviour), but blocked it in the mesolimbic
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structures (antagonism with aggressive behaviour and amphetamine-induced 
hyperlocomotion). Also selective interaction of clozapine with dopamine D4 receptors 
should be taken into account (Van Tol et al., 1991). Second, the interaction of 
clozapine with more than one receptor is apparently related to the action of drug. This 
is in agreement with the recent hypothesis that blockade of more than one receptor is 
necessary to achieve antipsychotic action with limited EPS (Kahn & Davidson, 1993; 
Seeman & Van Tol, 1994).
Selective dopamine D, antagonist SCH 23390 potently antagonized most 
behavioural effects of apomorphine, amphetamine and quipazine. SCH 23390 was 
rather effective against quipazine-induced head-twitches. This is not surprising since 
SCH 23390 had a significant affinity for б-Н Т^с receptors (IC50=19 nM). However, 
substantially higher doses of SCH 23390 were needed to block apomorphine-induced 
aggressiveness and stereotyped behaviour. This effect of SCH 23390 was 
accompanied by strong catalepsy. In fact the rats were unable to move at all. 
Therefore, the role of selective blockade of dopamine D, in the mechanism of action 
of antipsychotic drugs is rather doubtful. The correlation analysis revealed a 
relationship between behavioural effects of antipsychotic drugs and their affinity for 
dopamine D2 receptors, but not to other receptors. Consequently, the blockade of 
dopamine D2 receptors is essential for the action of antipsychotic drugs.
In subchronic studies marked differences between haloperidol and clozapine 
became evident. Repeated treatment with haloperidol reduced the affinity but 
increased the density of dopamine D2 receptors both in the striatum and mesolimbic 
area. The former effect could be explained by the presence of haloperidol in the brain 
even 72 hours after the discontinuation of treatment. However, the increased density 
of dopamine D2 receptors is probably the cause of hypersensitivity to the behavioural 
effects of dopamine agonists (stereotyped behaviour, hyperlocomotion) after the 
withdrawal of long-term haloperidol treatment (Jenner et al., 1985; Gordon et al.,
1987). By contrast, clozapine did not increase the number of dopamine D2 receptors 
in the brain. This may explain why withdrawal of long-term clozapine treatment did 
not increase the intensity of apomorphine-induced stereotypy. Moreover, repeated 
clozapine administration even tended to reduce this behaviour. Established lack of 
hypersensitivity at dopamine receptors is a likely reason of low incidence of EPS after 
long-term clozapine treatment. Furthermore, clozapine has been used to treat tardive 
dyskinesia caused by long-term antipsychotic treatment (Littrell & Magill, 1993; 
Tamminga et al., 1994). Clozapine, unlike haloperidol, increased the number of 
NMDA-gated channels in the open state and intensity of dizocilpine induced 
hyperlocomotion. This finding is obviously in favour of above described action of 
clozapine on the neurotransmission at NMDA-gated channels. In conclusion, 
interaction with several receptors in the brain, including dopamine D2, 5-HT2 and 
NMDA, seems to be important in the action of clozapine.
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6.3. Comparison of antipsychotic drugs and sigma antagonists
Several antipsychotic drugs (haloperidol, chlorpromazine) have a considerable affinity 
for sigma receptors (Su, 1982; Largent et a l, 1984; Tam & Cook, 1984). This was 
the first reason why sigma receptors were proposed to be the possible targets of 
antipsychotic action (Meltzer, 1991; Su, 1991). In various behavioural experiments 
sigma antagonists exerted a profile resembling in many ways that of atypical 
antipsychotic drugs. Rimcazole blocked apomorphine-induced climbing and 
aggressiveness but not stereotyped behaviour induced by dopamine agonist (Ferris et 
al., 1982). Rimcazole did not disrupt the conditioned avoidance behaviour and did not 
produce catalepsy either (Ferris et a l, 1982). Cinuperone inhibited apomorphine- 
induced climbing, but was too weak to block amphetamine-induced stereotyped 
behaviour (Hock et a l, 1985). Remoxipride antagonized apomorphine-induced 
hyperlocomotion and caused modest catalepsy only at high doses (ögren et al., 1984). 
BMY 14802 blocked apomorphine-induced hyperlocomotion and the conditioned 
avoidance behaviour (Taylor et a l, 1985). Moreover, BMY 14802 efficiently 
reversed catalepsy induced by haloperidol (Taylor et a l, 1985). However, it should 
be noted that the selectivity of these compounds is not high enough and other 
receptors are also involved into the action of sigma antagonists (Ferris et al., 1986b; 
Su, 1986; Largent et a l, 1988; Taylor & Dekleva, 1988). Therefore, to distinguish 
the role of sigma receptors in the action of antipsychotic drugs the sigma antagonists 
were compared with the typical and atypical antipsychotic compounds.
In the current study the sigma antagonists rather efficiently blocked several 
effects of apomorphine, amphetamine, and quipazine in acute experiments. Namely, 
they inhibited apomorphine-induced climbing and yawning, amphetamine- and 
dizocilpine-induced hyperlocomotion, and quipazine-induced head-twitches. 
Differently from haloperidol and chlorpromazine sigma antagonists (cinuperone, 
BMY 14802, rimcazole) did not block apomorphine-induced stereotypy at all or did 
it only at high doses (remoxipride). In this respect their pattern of action resembled 
that of atypical antipsychotic drugs. However, much higher doses of sigma 
antagonists were required compared to antipsychotic drugs and this does not support 
the idea that the existing sigma antagonists might be the strong antipsychotic drugs. 
Furthermore, sigma antagonists (except remoxipride), unlike antipsychotic drugs, 
were ineffective against apomorphine-induced aggressiveness even at very high doses. 
This is contradictory to the study of Ferris et al. (1982), where rimcazole was a potent 
antagonist of apomorphine-induced aggressiveness (Ferris et a l, 1982). However, in 
that study, an acute high challenge dose of apomorphine (5 mg/kg) was given to 
induce apomorphine-induced aggressiveness. This is entirely different from our 
approach in the present study. We employed the repeated apomorphine treatment at 
moderate doses, not inducing aggressive behaviour after the acute injection. In our 
study, doses of apomorphine as low as 0.25 mg/kg were able to evoke aggressive 
behaviour after the repeated treatment. Therefore, it is likely that subchronic
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administration of apomorphine causes the sensitization of dopamine receptors (to be 
discussed in the next chapter). Consequently, rimcazole was effective against 
apomorphine-induced aggressiveness when sensitivity of dopamine receptors linked 
to aggressive behaviour was low. It is likely that the antiaggressive effect of rimcazole 
established by Ferris et al. (1982) is not due to its interaction with sigma, but with 
dopamine D2 receptors. Indeed, rimcazole interacts with dopamine D2 receptors at low 
micromolar range.
The only preferential sigma antagonist showing marked effectiveness against 
apomorphine-induced aggressiveness was remoxipride. It also inhibited most 
behavioural effects induced by apomorphine, amphetamine and quipazine, and even 
at lower doses than clozapine did. It is important to note that remoxipride was 
described at first as a selective dopamine D2 antagonist (Ögren et al., 1984). Only 
later, was the high activity of remoxipride to sigma receptors established (Largent et 
al., 1988). In our studies remoxipride had ten-fold higher affinity for sigma receptors 
than for dopamine D2 receptors. Despite that the role of dopamine D2 receptors in the 
action of remoxipride should not be underestimated. Köhler et al. (1990) have 
demonstrated that in in vivo experiments the affinity of remoxipride for dopamine D2 
receptors was markedly higher than in in vitro studies.
Subchronic experiments with BMY 14802 are in favour of the idea that sigma 
receptors affect dopaminergic neurotransmission via presynaptie mechanisms. The 
motor depressant action of apomorphine, shown to be linked to stimulation of 
dopamine autoreceptors (Wilmot et al., 1989; Reith & Selmeci, 1992), was reversed 
after long-term administration of BMY 14802 and haloperidol. Haloperidol induced 
a significant upregulation of dopamine receptors in the striatum and mesolimbic area, 
whereas BMY 14802 did not induce any changes at dopamine receptors. By contrast, 
BMY 14802 increased the density of sigma receptors in the forebrain. Therefore, the 
different mechanisms in the action of haloperidol and BMY 14802 must be 
considered. Haloperidol, by increasing the density of dopamine D2 receptors, probably 
sensitized the postsynaptic dopamine receptors to the action of apomorphine. The 
increased sensitivity of postsynaptic dopamine receptors is a likely reason why 
dopamine agonist was not able to cause motor depression after long-term treatment 
with haloperidol. The action of BMY 14802, differently from haloperidol, seems to 
be related to the inhibition of presynaptie dopaminergic mechanisms. The repeated 
treatment with BMY 14802 is shown to inhibit electrical activity of dopamine 
neurons in the ventral tegmental area (Wachtel & White, 1988).
In chronic experiments, haloperidol is shown to decrease (Bremer et al., 1989; 
Itzhak & Alerhand, 1989; Matsumoto et al., 1989) and rimcazole to increase the 
number of sigma binding sites in the rat brain (Mariallack & Beart, 1988; Beart et al.,
1989). These findings were confirmed by the present study. Repeated treatment with 
haloperidol markedly reduced the density of sigma receptors in the cerebellum, 
whereas sigma antagonist BMY 14802 increased the number of these receptors in the 
frontal cortex. The down-regulation of a particular receptor is usually related to the
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repeated action of a drug having the agonistic action at this receptor. Thus, the 
decrease of sigma receptors by haloperidol can be taken as a sign of agonistic, but not 
antagonistic interaction with sigma receptors. This opinion is in accordance with the 
studies of Walker et al. (1988) where the microinjections of haloperidol, like sigma 
agonists (+)-SKF 10,047, (+)-pentazocine, dextrallorphan and DTG, into the red 
nucleus caused significant dystonia in rats. Consequently, the possiblity exists that 
sigma receptors may mediate one of the side effects of antipsychotic treatment — 
dystonia.
Two possible mechanisms should be taken into account to explain the 
behavioural effects of sigma antagonists against dopamine agonists. First, sigma 
receptors located at dopamine neurons and nerve terminals are shown to stimulate the 
release of dopamine (Matthews et al., 1986). Therefore, sigma antagonists reduce the 
dopaminergic activity by blocking these sigma receptors. Second, they interact 
directly with dopamine receptors. The data of correlation analysis are rather in favour 
of this statement since it revealed a strong positive relation between the behavioural 
effects of studied drugs and their affinity for dopamine D2 receptors. Comparison of 
action of sigma antagonists at sigma receptors and in behavioural studies established 
only weak and negative correlation. Therefore, it is likely that at least some effects of 
sigma antagonists are linked to their weak activity at dopamine D2 receptors, but not 
to their interaction with sigma receptors. There are two more arguments in favour of 
this statement. Clozapine and raclopride, the drugs having significant antipsychotic 
action, did not influence the activity of sigma receptors at all. Remoxipride, despite 
considerable affinity for sigma receptors, exerted the majority of its effects via 
blocking of dopamine D2 receptors.
In conclusion, it is very unlikely that the existing sigma receptor antagonists could 
be used as antipsychotic drugs with strong action. The moderate antipsychotic-like 
action of sigma antagonists in the behavioural studies is probably related to their 
weak interaction with dopamine D2 receptors.
6.4. Apomorphine-induced aggressiveness: a model to reveal and 
study new antipsychotic drugs
Psychotic disorders are mainly chronic diseases. Therefore, acute animal models can 
hardly be reliable to reveal new antipsychotic drugs and study their mechanism of 
action. Previous parts of current investigation are in favour of that. Sigma antagonists 
that effectively work in acute behavioural models were completely ineffective against 
apomorphine-induced aggressiveness. Accordingly, subchronical models should be 
used to reveal and study antipsychotic drugs.
Aggressiveness induced by a single high dose of apomorphine has been found to 
be a sensitive test to reveal antipsychotic activity of drugs. Both typical and atypical 
antipsychotic drugs blocked this aggressiveness. However, aggressive behaviour can
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be induced also by repeated injections of moderate doses of apomorphine for 10-15 
days (Allikmets & Vasar, 1982; Porreca et al., 1982). Repeated treatment with 
dopamine agonists induces sensitization of dopaminergic system, which appears as 
increased motor activity and aggressiveness (Rowlett et al., 1991; Druhan et al., 
1993; McNamara etal., 1993).
Our data agree with the results of earlier studies (Allikmets & Vasar, 1982; 
Porreca et al., 1982) which showed that repeated injections of apomorphine at 
moderate doses (0.5-1 mg/kg) induced aggressive behaviour in the rats. On the 7th 
day of repeated apomorphine treatment all rats became aggressive. Apomorphine- 
induced aggressiveness was very steady. Once induced, every subsequent injection of 
apomorphine caused a similar behaviour. Even a single treatment with apomorphine 
3 months after the last injection of the 10-day apomorphine regimen induced 
aggressive behaviour.
Haloperidol and chlorpromazine did not show any selectivity for apomorphine- 
induced aggressiveness over other behaviours. They blocked apomorphine-induced 
stereotyped behaviour and aggressiveness at equal dose. However, several drugs 
belonging to atypical antipsychotic drugs (raclopride, clozapine, remoxipride, SCH 
23390) antagonized apomorphine-induced aggressiveness at much lower doses as 
compared to stereotyped behaviour. Consequently, the target of antipsychotic action 
of atypical compounds seems to be the mesolimbic dopaminergic system related to 
aggressive behaviour, but not to the induction of stereotyped behaviour. Differently 
from the experiments of Levy et al. (1988) and Mattingly et al. (1991) the role of 
dopamine D, receptors in the development of aggressive behaviour is less evident as 
compared to that of dopamine D2 receptors. Indeed, the data of present study are 
strongly in favour of dopamine D2 receptor to be a major target of apomorphine- 
induced aggressiveness. There is a good correlation between antiaggressive action of 
antipsychotic drugs and their affinity for dopamine D2 receptors (r=0.86). However, 
we were not able to detect any changes at dopamine D2 receptors after a long-term 
treatment with apomorphine. This is in accordance with earlier studies showing that 
repeated administration of dopamine agonists did not change the parameters of striatal 
dopamine receptors in mice and rats (Riffee et al., 1982; Jenner et al., 1988). 
Therefore, one can state that the other mechanisms must be involved.
Dizocilpine, a non-competitive NMDA antagonist, has been shown to block the 
sensitization of rats to apomorphine-induced hyperlocomotion (Druhan et al., 1993). 
Therefore, we used dizocilpine to reveal the involvement of NMDA-gated channels 
in the development of apomorphine-induced stereotypy. Dizocilpine (0 .01-0.5 mg/kg) 
blocked aggressive behaviour at doses 0.25 mg/kg or higher. This effect was 
accompanied by marked impairment of motor coordination in rats. Thus, the 
specificity of antiaggressive effect of dizocilpine remains questionable at this point. 
Nevertheless, coadministration of dizocilpine (0.25 mg/kg) with apomorphine 
blocked, whereas a low dose of dizocilpine (0.025 mg/kg) even accelerated the 
development of aggressive behaviour. The blockade of apomorphine-induced
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behavioural sensitization by dizocilpine is in good correlation with the studies of 
Druhan et al. (1993). Accordingly, NMDA-gated channels are involved in the 
changes of emotional behaviour induced by apomorphine, as they are implicated in 
the development of increased motor activity. The acceleration of development of 
apomorphine-induced aggressive behaviour by 0.025 mg/kg of dizocilpine might be 
related to the NMDA agonist-like effect of low doses of dizocilpine. This 
proaggressive action of dizocilpine seems to support the specific nature of anti- 
aggressive effect of NMDA antagonist at high doses. The background of such action 
of dizocilpine is not clear, but could be related to the accelerated development of 
increased sensitivity at NMDA-gated channels and subsequently at dopamine D2 
receptors.
Repeated administration of apomorphine increased the density of dizocilpine 
labelled NMDA-gated channels in the two brain regions studied (the frontal cortex 
and hippocampus). Acute exposure of these rats to apomorphine induced a marked 
down-regulation (to the level of control animals) of NMDA channels in the frontal 
cortex and striatum. Therefore, one could speculate that apomorphine induced a 
significant release of endogenous ligands for NMDA-gated channels (glutamate, 
aspartate) which desensitized their receptors.
It is very likely that NMDA-gated channels play one of the key roles in the 
development of apomorphine-induced aggressive behaviour. Repeated treatment with 
apomorphine increased the density of NMDA-gated channels in the open state since 
dizocilpine is the antagonist of open NMDA channels (Sills & Loo, 1989). These 
changes at NMDA-gated channels somehow affect the functioning of dopamine D2 
receptors without altering their number or affinity for [3H]-spiperone. This poorly 
characterized phenomenon seems to be the main reason for the development of 
apomorphine-induced aggressive behaviour.
In conclusion, apomorphine-induced aggressiveness is a more valid model of 
psychotic behaviour than the behavioural effects induced by acute administration of 
apomorphine, amphetamine, and quipazine. There is a correlation between 
antipsychotic activity of drugs and their antiaggressive action in the described model. 
The sensitization of dopamine D2 receptors seems to play the central role in the 
development of this behaviour. The increase of NMDA-gated channels in the open 
state is a possible reason of increased sensitivity at dopamine D2 receptors.
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7. CONCLUSIONS
1. The results of radioligand binding studies are in favour of involvement of dopamine 
D2, S -H T ^ c and sigma receptors in the action of antipsychotic drugs and sigma 
antagonists. Haloperidol displayed high affinity for dopamine D2 and sigma receptors, 
whereas chlorpromazine preferentially interacted with dopamine D2 and З -Н Т ^ с  
receptors. Raclopride was the selective ligand for dopamine D2 receptors and 
clozapine displayed significant affinity for б -Н Т ^с receptors. SCH 23390 had very 
high affinity for dopamine D, receptors, but it also interacted with б -Н Т ^с  
receptors. Sigma antagonists (cinuperone, remoxipride, BMY 14802 and rimcazole) 
had a preferential action on sigma receptors, but they also had very variable affinity 
for dopamine D2 and б-Н Т ^с receptors.
2. Atypical antipsychotic drugs (clozapine, raclopride, remoxipride), unlike typical 
ones (haloperidol, chlorpromazine), possess the selectivity for dopamine D2 receptors 
in the mesolimbic area. These drugs were much stronger antagonists of apomorphine- 
induced aggressiveness and amphetamine-induced hyperlocomotion compared to 
apomorphine-induced stereotyped behaviour. Atypical antipsychotic drugs clozapine 
and SCH 23390 are also potent antagonists of 5-HT2 receptors in the behavioural 
studies. They blocked in low doses quipazine-induced head-twitches in rats. 
Clozapine, unlike the other antipsychotic drugs, interacted with NMDA-gated 
channels. Repeated treatment with clozapine increased the density of NMDA-gated 
channels in the frontal cortex. This effect of clozapine was accompanied by the 
augmented response to dizocilpine, a non-competitive antagonist of NMDA, induced 
hyperlocomotion.
3. The behavioural pattern of sigma antagonists resembled that of atypical 
antipsychotic drugs. However, sigma antagonists did not antagonize apomorphine- 
induced aggressiveness. The weaker behavioural activity of sigma antagonists is 
probably related to their modest antagonistic activity at dopamine D2 receptors. 
Repeated treatment with haloperidol, differently from BMY 14802, induced the 
down-regulation of sigma receptors in the brain. Thus, it is very unlikely that the 
blockade of sigma receptors plays a major role in the action of antipsychotic drugs.
4. Apomorphine-induced aggressiveness is a reliable model to mimic psychotic 
behaviour in rats. This model clearly distinguishes the action of antipsychotic drugs 
and sigma antagonists. There was positive correlation between the antipsychotic 
activity of drugs and their antiaggressive action in the described model. Repeated 
administration of moderate doses of apomorphine caused persistent emotional and 
behavioural changes in rats. The sensitization of dopamine D2 receptors is probably 
a key mechanism in the development of this behaviour. The increased number of
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NMDA-gated channels in the open state is a likely reason for enhanced sensitivity of 
dopamine D2 receptors.
5. In general, the results of in vitro binding and behavioural studies confirm that the 
action of tested antipsychotic compounds is related mainly to their activity at 
dopamine D2 receptors. The correlation analysis revealed a good correlation between 
the potency of tested compounds in the behavioural experiments and their affinity for 
dopamine D2 receptors. However, clozapine had also a significant interaction with 5- 
HT2PJ2C receptors and NMDA-gated channels. The interaction of clozapine with 
several neurotransmitter systems may explain its unusual antipsychotic action.
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DOPAMIINI, 5-HÜDROKSÜTRÜPTAMIINI, 
SIGMA JA NMDA RETSEPTORITE ROLL 
ANTIPSÜHHOOTILISTE AINETE TOIMES
Kokkuvõte
Antipsühhootilised ravimid on keemiliselt heterogeense struktuuriga ained, kuid 
enamik antipsühhootikume on tugevad dopamiini D2 retseptorite antagonistid 
(Seeman, 1980; Richelson, 1984). Paraku on tüüpiliste antipsühhootiliste ainete 
pikaajaline kasutamine seotud ekstarpüramidaalhäirete tekkega. Seeman ja Van Tol 
(1994) oletavad, et edukaks kõrvaltoimetevabaks antipsühhootiliseks raviks on lisaks 
dopamiini D2 retseptorite blokaadile vaja ravimi toimet ka teistel retseptoritel. 
Tõepoolest, risperidoon ja klosapiin, blokeerides dopamiini D2, 5-hüdroksü- 
trüptamiini 5-HT2A ja 5-HT2C retseptoreid, kõrvaldavad skisofreenia positiivse ja 
negatiivse sümptomaatika, põhjustamata sealjuures olulisi ekstrapüramidaalhäireid 
(Leysen et al., 1993).
Viimastel aastatel on antipsühhootikumide ühe võimaliku toimepunktina 
käsitletud sigma retseptoreid. Nimelt omavad mitmed antipsühhootilised ravimid 
sigma retseptorite suhtes isegi suuremat afimsust kui dopamiini retseptorite suhtes 
(Tam, 1983; Tam & Cook, 1984; Largent et al., 1988). Samuti on kindlaks tehtud 
anatoomiline ning funktsionaalne seos sigma retseptorite ja dopamiinergilise süsteemi 
vahel ajus (Graybiel et al., 1989; Taylor et al., 1990; Walker et al., 1990). 
Antipsühhootiliste ainete toimes peetakse oluliseks ka glutamaati ja NMDA- 
retseptorkompleksi, sest glutamaat reguleerib NMDA-retseptorkompleksi kaudu 
dopamiini vabanemist aju mitmetes piirkondades (Whitton et al., 1994) ja mõjutab 
tugevasti dopamiinergilist närviülekannet striatumis (Martinez-Fong et a l,  1992; 
Whitton et a l,  1994). NMDA-retseptorkompleksi kuuluv mittespetsiifiline 
katioonkanal on oluline fentsüklidiini ja samaste ainete psühhootomimeetilises toimes 
(Javitt & Zukin, 1991), sest kõik need ained blokeerivad nimetatud kanali (Wong et 
al., 1986). Retseptorisidumis- ja käitumiskatsete tulemused lubavad väita, et 
atüüpiline antipsühhootikum, klosapiin, interakteerub nimetatud sidumiskohaga 
(Janowsky & Berger, 1989; Tiedtke et al., 1990). On isegi väidetud, et klosapiini 
toime skisofreenia negatiivse sümptomaatika leevendamisel võib olla seotud tema 
toimega NMDA-kanalitele (Tiedtke et a l, 1990; Schmidt et a l,  1991).
Eelnevast lähtudes oli antud töö eesmärgiks täpsustada arusaamu antipsühhootiliste 
ainete võimalikest toimemehhanismidest. Selle probleemi lahendamiseks püstitati 
kolm konkreetsemat ülesannet:
1) Võrrelda tüüpilisi ja atüüpilisi antipsühhootilisi aineid retseptori- 
sidumiskatsetes ja eksperimentaalsetes käitumuslikes mudelites, mis peegeldavad
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ainete antipsühhootilist aktiivsust. Erilist tähelepanu pöörati nende ainete 
interaktsioonile dopamiini, sigma, 5-HT2A/2C retseptoritega ja NMDA- 
retseptorkompleksiga.
2) Selgitada sigma retseptorite tähtsust antipsühhootiliste ainete toimes. Sel 
eesmärgil võrreldi selektiivsete sigma retseptorite antagonistide ja antipsühhootiliste 
ainete ühekordse ja kestva manustamise efekte käitumuslikes ja radioligand- 
uuringutes.
3) Senises praktikas on ainete antipsühhootiliste toime selgitamiseks rakendatud 
peamiselt akuutsete psühhoosilaadsete seisundite modelleerimist katseloomadel, 
kasutades psühhootomimeetiliste ainete ühekordset manustamist. Skisofreenia ja 
mitmed teised psühhootilised seisundid on aga kroonilise iseloomuga haigused. 
Eeltoodut silmas pidades oli otstarbekas rakendada meetodit, mis modelleeriks 
kestvat psühhootilist seisundit. Selleks manustati rottidele korduvalt apomorfiini, mis 
kutsus neil esile agressiivse käitumise. Eksperimentide käigus püüti selgitada mudeli 
adekvaatsust ainete antipsühhootilise toime uurimisel, samaaegselt uuriti täpsemalt 
NMDA-kanalite osa agressiivse käitumise kujunemisel.
Käesoleva töö in vitro retseptorisidumiskatsete tulemused on kooskõlas hüpoteesiga, 
et dopamiini D2, 5-HT2A/2Cja sigma retseptorid osalevad antipsühhootiliste ainete ja 
sigma antagonistide toimes. Haloperidool oli väga afiinne dopamiini D2 ja sigma 
retseptorite suhtes, samal ajal kui kloorpromasiin interakteerus eelistatult dopamiini 
D2 ja 5-HT2A/2C retseptoritega. Klosapiin omas aga olulist afiinsust 5-HT2A/2C 
retseptoritel. SCH 23390 oli väga afiinne dopamiini D, retseptorite suhtes, kuid ta 
interakteerus ka retseptoritega. Sigma antagonistid (tsinuperoon,
remoksipriid, BMY 14802 ja rimkasool) toimisid eelistatult sigma retseptoritel, kuid 
nende afiinsus dopamiini D2 ja 5-HT2A/2C retseptorite suhtes oli varieeruv. Tuginedes 
käitumiskatsete ja in vitro retseptorisidumiskatsete tulemustele, võib kinnitada, et 
uuritud ainete antipsühhootiline efekt on eelkõige seotud nende aktiivsusega 
dopamiini D2 retseptoritel. Korrelatsioonianalüüs tõi ilmsiks olulise seose ainete 
käitumusliku toime ja nende afiinsuse vahel dopamiini D2 retseptorite suhtes.
Erinevalt tüüpilistest (haloperidool, kloorpromasiin) antipsühhootilistest ainetest 
toimisid atüüpilised (klosapiin, raklopriid ja remoksipriid) eelistatult mesolimbiliste 
dopamiini D2 retseptorite kaudu. Atüüpilised antipsühhootikumid antagoniseerisid 
apomorfiini agressiivsust ja amfetamiini hüperlokomototsiooni märksa väiksemates 
annustes kui apomorfiini poolt põhjustatud stereotüüpset käitumist. Atüüpilised 
antipsühhootikumid, klosapiin ja SCH 23390, blokeerisid efektiivselt kvipasiinist 
tingitud pearaputusi rottidel, demonstreerides sellega oma tugevat toimet 5-HT2A/2C 
retseptoritel. Erinevalt teistest antipsühhootilistest ainetest toimis klosapiin ka 
NMDA-retseptorkompleksile. Klosapiini korduv manustamine suurendas avatud 
NMDA-kanalite hulka frontaalses koores. Klosapiini sellise retseptoorse efektiga 
kaasnes NMDA mittekonkureeriva antagonisti ditsotsilpiini motoorikat stimuleeriva 
toime tugevnemine. Klosapiini omapärane antipsühhootiline toimespekter on seega
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põhjendatav aine toimimisega mitmetele erinevatele virgatsainesüsteemidele 
(dopamiin, 5-HT ja glutamaat).
Sigma antagonistide aktiivsus käitumiskatsetes meenutas atüüpiliste 
antipsühhootikumide toimespekterit. Ainsa olulise erinevusena sigma antagonistid ei 
blokeerinud apomorfiini agressiivsust. Sigma antagonistide suhteliselt nõrk aktiivsus 
käitumiskatsetes on ilmselt seotud nende nõrga antagonistliku toimega dopamiini D2 
retseptoritel. Oluline on ka mainida, et haloperidooli korduv manustamine erinevalt 
sigma antagonisti BMY 14802 manustamisest põhjustas sigma retseptorite hulga 
vähenemise ajus. Seetõttu on ebatõenäoline, et sigma retseptorite blokaad omaks 
olulist rolli antipsühhootiliste ainete toimes.
Apomorfiini mõõdukate annuste korduv manustamine kutsus esile püsiva 
agressiivse käitumise rottidel. Selles mudelis eristus selgelt antipsühhootiliste ainete 
ja sigma antagonistide toime. Eksisteeris tugev positiivne korrelatsioon ainete 
antipsühhootilise aktiivsuse ja antiagressiivse toime vahel antud mudelis. Püsivate 
käitumuslike muutuste tekkimisel omab ilmselt peamist tähtsust dopamiini D2 
retseptorite sensitiseeerumine. Dopamiini D2 retseptorite suurenenud tundlikkuse 
kujunemise üheks põhjuseks on arvatavasti avatud olekus NMDA-kanalite hulga 
suurenemine. Läbiviidud katsed lubavad väita, et apomorfiini agressiivsus on 
adekvaatseks mudeliks psühhootilise käitumise uurimisel rottidel.
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Abstract: An atypical antipsychotic drug clozapine and a selective sigma antagonist BMY 14802 were significantly less 
effective in the behavioural experiments (against apomorphine, d-amphetamine and MK-801), as well in the radioligand 
binding studies against !H-spiperone (dopamine2-receptors) and 3H-haloperido! (sigma receptors) in the rat brain, as 
compared to a typical antipsychotic compound haloperidol. Contrary to haloperidol and BMY 14802, clozapine was a 
relatively selective antagonist of MK-801-induced m otor excitation in the mouse. A nearly 3-fold lower dose of clozapine 
was needed to block the effect o f MK-801 (6.4 nm ol/kg) as compared to the action of amphetamine (17 (imol/kg). 
Haloperidol and clozapine, but not BMY 14802, antagonized apomorphine-induced aggressiveness in the rat. After long­
term treatment (for 15 days) with BMY 14802 (10 m g/kg daily), haloperidol (0.5 m g/kg daily) and clozapine (10 m g/kg 
daily) the m otor depressant effect o f apomorphine (0.15 m g/kg) was reversed. Chronic haloperidol treatm ent, but not 
administration of BMY 14802 and clozapine, increased the num ber o f dopamine,-receptors in the rat brain. BMY 14802 
caused upregulation of sigma receptors in frontal cortex, whereas haloperidol induced the opposite change in cerebellum. 
Repeated treatm ent with clozapine significantly augmented the m otor stimulating effect o f MK-801 in rats. Simultaneously 
with a behavioural change the density of 3H-TCP binding sites in the rat forebrain was elevated after long-term treatment 
with clozapine, probably indicating the involvement of PCP binding sites a t NM D A channel in the action o f clozapine.
Martin et al. (1976) have identified sigma opiate receptors 
as the sites accounting for the “mania” induced by N- 
allylnormetazocine (SKF 10,047) and related benzomor- 
phans in spinal dogs. The psychotomimetic action of benzo- 
morphans have since been attributed to non-opioid binding 
sites that are not sensitive to naloxone and etorphine (Su 
1982). In radioligand binding studies an important separ­
ation has been made between two distinct binding sites for 
SKF 10,047: 1) the phencyclidine (PCP) site with low affin­
ity for SKF 10,047, is known to be related to the N-methyl- 
D-aspartate (NMDA) subtype of glutamate receptor; 2) a 
site with high affinity for SKF 10,047, which is now known 
as the sigma receptor (Largent et al. 1986; Tam 1985). This 
sigma receptor exhibits high affinity for some neuroleptic 
drugs, e.g. haloperidol, chlorpromazine, remoxipride 
(Largent et al. 1986 & 1988; Taylor & Dekleva 1987). Rim- 
cazole and BMY 14802 were shown to be relatively selective 
ligands at sigma binding sites in CNS tissues with no ap­
preciable affinity for dopamine receptors (Ferris et al. 1986; 
Taylor & Dekleva 1988). A putative sigma antagonist rimca­
zole has been shown to cause the upregulation of rat cortical 
sigma receptors after subchronic administration (Manal- 
lack & Beart 1988).
Several studies suggest a significant functional connection 
of PCP and sigma receptors with the mesolimbic and cort­
ical dopaminergic neurones. According to Deutch et al. 
(1987) PCP increases dopamine release in the mesolimbic/ 
cortical region and decreases it in nigrostriatal structures. 
The sigma receptor agonist ( +  )SKF 10,047 is shown to
* To whom correspondence should be directed.
stimulate the activity of dopamine neurones in the ventral 
tegmental area (A,0) of the rat brain (Freeman & Bunney 
1984) innervating the nucleus accumbens, lateral septum, 
prefrontal cortex and olfactory tubercle (Dahlström & Fuxe 
1964). Rimcazole, an antagonist at sigma sites, effectively 
antagonizes ( +  )SKF 10,047-induced excitation of dop­
amine neurones in the ventral tegmental area, while having 
no effect on spontaneous firing o f A10 neurones (Ceci et al. 
1988). Wachtel & White (1988) have demonstrated that the 
repeated administration of the selective sigma antagonist 
BMY 14802, like that of the atypical neuroleptic drug cloza­
pine, reduces the number of spontaneously active dopamine 
cells in ventral tegmental area without affecting the activity 
of dopamine cells in the substantia nigra. The observation 
that benzomorphans with high affinity at the sigma receptor 
are psychotomimetics in humans has prompted the sugges­
tion that the selective antagonists at the sigma receptor may 
represent a class of novel antipsychotic compounds without 
extrapyramidal side effects (Tam et al. 1988). Janowsky & 
Berger (1989) have demonstrated that clozapine, moderately 
active compound at dopamine: receptors, is a rather potent 
inhibitor of 3H-MK-801 binding in the rat brain, suggesting 
the interaction of clozapine with PCP binding sites. Byrd 
et al. (1987) have shown that long-term treatment with 
haloperidol increases significantly the density o f PCP bind­
ing sites in the rat brain. Thus, to establish the role of 
dopamine2-, PCP and sigma receptors in the action of anti­
psychotic drugs we have compared the effects of acute and 
chronic treatment with the classical neuroleptic drug halop­
eridol, the atypical-antipsychotic compound clozapine and 
the selective antagonist at sigma receptors BMY 14802 in 
behavioural and radioligand binding experiments.
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Table 1.
Antagonism of haloperidol, clozapine and BMY 14802 to the behavioural effects o f apomorphine, amphetamine and MK-801 in rodents 
and the inhibition o f in vitro 3H-radioiigand binding by haloperidol, clozapine and BMY 14802 in ra t brain.
Drug-induced behaviour Haloperidol Clozapine
Ratio 
CLZ vs. HAL BMY 14802
Ratio 
BMY vs. HAL
Apomorphine-induced yawning (rat) 0.13 3.4 26 7.5 58
(0.08-0.36) ( 1 .1- 8 .0 ) (1.5-14.4)
Apomorphine-induced climbing (mouse) 0.35 24.0 69 45.0 129
(0.22-1.3) (8.3-46.2) (20.1-67.1)
Amphetamine-induced m otor excitation (mouse) 0.37 17.0 46 30.0 81
(0.26-0.7) (10.1-29.3) (16.4-50.0)
MK-801-induced m otor excitation (mouse) 0.43 6.4 15 27.0 63
(0.27-0.56) (3.4-11.9) (7.8-68.0)
Apomorphine-induced stereotypy (rat) 0.67 >31 > 46 >115 > P 2
Apomorphine-induced aggressiveness (rat) 0.67 31 46 >115 >172
Radioligand binding
3H-spiperone binding in striatum 5.5±0.8 300 ±25 55 5100±420 927
’H-haloperidol binding in frontal cortex 1.8 ±0 .4 > 1 0 0 0 0 >5555 92 ±10 51
The table presents E D W values (nmol/kg) o f compounds and confidence limits for them. The doses o f compunds, compleiely blocking the 
behaviour are shown only in the case o f  apomorphine-induced stereotyped gnawing and aggressiveness. The results of radioligand binding 
studies are presented as IC*, values ±S .E .M . in nM.
Materials and Methods
Animals. Male albino rats, weighing 250-300 g, and male albino 
mice, weighing 25-30 g, were used in the experiments. Animals were 
kept under standard laboratory conditions (temperature 2 0  ±3°), 
with free access to food and water.
Acute behavioural studies.
Apomorphine-induced yawning in rats. The test was performed as 
described by Morelli et al. (1986). Haloperidol, clozapine and BMY 
14802 were injected intraperitoneally 30 min. before the administra­
tion o f apomorphine. The num ber o f  yawns was counted during 1 
hr after treatm ent with apomorphine (0 .1  m g/kg, subcutaneously). 
The commercial solution o f haloperidol (Gedeon Richter, Hungary) 
was diluted in saline, BMY 14802 (Bristol-Myers, U.S.A.) was 
dissolved in saline and clozapine (Sandoz, Switzerland) was sus­
pended in saline with the help of 1-2 drops o f Tween-85 (Ferak, 
Germany).
Apomorphine-induced climbing in mice was studied according to 
the method o f M oore & Axton (1988): apomorphine (3 m g/kg, 
subcutaneously) and test compounds were injected respectively 5 
min. and 30 min. prior to the placement o f animals into individual 
wire net cages, where the climbing activity was registered during 30 
min.
Amphetamine- and MK-801-induced motor excitation in mice was
measured in individual cages (Vasar et al. ?0). The cage was a 
cylinder (diameter 40 cm) with 2 photoce. located in the wall. 
Locom otor activity was counted between x5 and 45 min. after 
administration of d-amphetamine (7.5 m g/kg, subcutaneously) or 
MK-801 (( +  )-5-methyl-10,l l-dihydro-5-H-dibenzo[a,d]cyclohept- 
an-5,10-imine maleate) (0.25 m g/kg, intraperitoneally). The test 
compounds were injected 30 min. before the measurement o f m otor 
activity.
The ED » values for all drugs were calculated from the dose- 
response curves.
Apomorphine-induced stereotyped behaviour in rats. Apomorphine 
(0.5 m g/kg, subcutaneously) was injected 30 min. and the test drugs 
60 min. prior to the registration o f stereotyped behaviour according 
to the scale o f  Costall & Naylor (1974). Stereotyped behaviour was 
measured simultaneously with aggressive behaviour.
Apomorphine-induced aggressiveness was studied in the grouped 
animals ( 8  rats in the test cage). The animals were sensitized previous 
to apomorphine aggressiveness by 3-weeks chronic treatment with 
apomorphine (0.5 m g/kg twice daily, subcutaneously) (Allikmets & 
Vasar 1982). The number of rats showing apomorphine-induced 
(0.5 m g/kg, subcutaneously) aggressive behaviour was registered. 
Haloperidol, clozapine and BMY 14802 were administered 30 min. 
before the treatm ent with apomorphine. In the case o f  apom orph­
ine-induced stereotyped behaviour and aggressiveness the dose of 
drug which produced a complete blockade of the behavioural effects 
of apomorphine was registered.
Table 2.
The effect o f repeated administration (for 15 days) of haloperidol (0.5 m g/kg daily), clozapine (10 m g/kg) and BMY 14802 (10 m g/kg) on 
behavioural effects o f MK-801 (0.2 m g/kg) in the rat
Treatment
Intensity of 
stereotyped behaviour
Intensity of 
ataxia
No. of lines 
crossing
No. of 
rearings
Saline +  saline - _ 48 ±4* 8.4 ±1 .4
Saline +  MK-801 1.3 ±0.3 1.3±0.3 97 ±14* 1.4 ± 0 .3 '
Haloperidol +  MK-801 1.6±0.3 1.8 ±0.3 118 ±  12 2.3±0.8
Clozapine +  M K-801 1.3±0.3 1.8  ±  0.3 139 ± 19b 6 .0 ± 2 .7 b
BMY 14802 + MK-801 1.3 ±0 .2 1 .1  ± 0 .2 120 ±  23 2.0 ±0 .9
MK-801 was administered 72 hr after the administration of haloperidol, clozapine or BMY 14802. Saline o r MK-801 were injected 30 min. 
before the experiment. *-P<0.05 (as compared to saline +  saline-treated animals); b-P < 0 .05  (as compared to saline +  M K-801-treated 
animals), M ann-W hitney U-test.
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Table 3.
The effect o f repeated administration (for 15 days) of haloperidol (0.5 m g/kg daily), clozapine (10 m g/kg daily) and BMY 14802 (10 mg/ 
kg daily) on behavioural effects of apomorphine (0.15 m g/kg) in the rat.
Treatment
Intensity of 
stereotyped behaviour
No. of line 
crossings
No. of 
rearings
No, of 
head-dips
Saline +  saline - 27.3 +  4.4 13.1 ±2.8 3.0 ±0.8
Saline +  apomorphine 3.0±0.1 14.3 ±2.5* 4.1 +2.0* 1.3±0.4*
Haloperidol +  apomorphine 2 .8±0.3 21.6 ±3 .0 4 .8+  3.5” 4 .4 ± 0 .6 b
Clozapine +  apomorphine 2 .3±0 .3b 25.0 +  4.7b 8 .0 ± 2 .6 b 2.8 ±0 .9
BMY 14802 + apomorphine 2.8 ±0.4 29.0±4 .5b 8 .8  ±  3.4b 4 .3 ± 1 .3 b
Apomorphine was injected 72 hr after the last injection of saline, haloperidol, clozapine or BMY 14802. The behaviour o f rats was registered 
15 min. after the administration of saline or apomorphine. a-P < 0.05 (as compared to saline +  saline-treated animals); b-P < 0 .05  (as compared 
to saline +  apomorphine-treated animals), M ann-W hitney U-test.
Behavioural studies after chronic treatment. Haloperidol (0.5 m g/kg 
daily, intraperitoneally), clozapine ( 1 0 .0  m g/kg daily, intraperit- 
oneally) and BMY 14802 (10.0 m g/kg daily, intraperitoneally) were 
administered for 15 days. Seventy-two hr after the last injection of 
test drugs, MK-801-induced behaviour was investigated. MK-801 
(0.2 m g/kg) was administered subcutaneously 30 min. prior to 
the registration of stereotyped behaviour according to the scale of 
Costall & Naylor (1974). Then the animals were placed in the open 
field (I x 1 x0 .4  m). The num ber o f line crossings and rearings 
during 5 min. was counted. The intensity o f ataxia was measured 
according to the method of Contreras et al. (1986). Apomorphine- 
induced behaviour was also investigated 72 hr after the last injection 
o f haloperidol, clozapine and BMY 14802. Apomorphine (0.15 m g/ 
kg) was injected subcutaneously 15 min. prior to the experiment. 
The intensity o f stereotyped gnawing (Costall & Naylor 1974), the 
number o f line crossings, rearings and head-dippings in the open 
field were registered.
Binding studies. For binding studies the animals were killed by 
decapitation 72 hr after the last injection of drugs. The brains 
were rapidly removed from the skull and the brain structures were 
dissected on the ice. The brain structures were stored at -  20° until 
the following procedures. Brain tissues were thawed on the day of 
the experiment. Pooled tissues from 4 animals were used in all 
radioligand experiments. Tissues were homogenized with a Potter- 
S homogenizer in 20 vol. ice-cold 50 mM Tris-HCl buffer (pH 
7.4 or 7.7 in the case o f 3H-spiperone, !H-haloperidol or 3H-TCP, 
respectively). Membranes were washed twice by centrifugation at 
48000 x g  for 15 min. After the last centrifugation the tissues were
suspended in the incubation buffer for the appropriate binding 
assay. The radioligand binding studies were repeated at least three 
times.
3H-Spiperone (109 Ci/m m ol, Amersham, final concentrations 
0.06-2 nM ) was incubated for 30 min. at 37° with the membrane 
preparation (1 mg wet weight/tube) in 0.5 ml of incubation buffer 
consisting of Tris-HCl 50 mM, NaCl 120 mM, K.C1 5 mM, CaCl2 
2 mM, MgCl2 1 mM (pH 7.4). The non-specific binding was deter­
mined in the presence of 500 nM raclopride. The reaction was 
stopped by rapid centrifugation at 11,000 x g for 4 min.
!H-Haloperidol binding. To define specific binding, homogenates 
( 1 2  mg wet weight/tube) were incubated with increasing concen­
trations (2.5-80 nM) o f pHJhaloperidol (8.9 Ci/m m ol, NEN) in the 
absence and presence o f 10 цМ haloperidol. Raclopride (500 nM) 
was added to each tube to block 3H-haloperidol binding to dop- 
amine3 receptors. Incubation was carried out a t room  temperature 
in a total volume of 1 ml 50 mM Tris-HCl buffer (pH 7.7). After 
a 90 min. incubation at room temperature m embrane-bound 5H- 
haloperidol was separated from free radioligand by rapid filtration 
through W hatman G F /B  glass fibre filters that were presoaked with 
0.05% polyethyleneimine. After filtration, the filters were washed 
twice (4.5 ml each) with incubation buffer.
PCP binding sites were detected on membranes using 7.5 nM  5H- 
TCP (60 C i/m m ol, NEN) in the presence o f 2-100 nM  of MK.-801. 
The incubation of brain membranes (12 mg wet weight/tube) was 
carried out in the total volume o f 0.5 ml 5 mM  Tris-HCl buffer (pH 
8.1 at 20°) for 45 min. at room  temperature. The incubation was 
terminated by rapid filtration as described above.
The mean apparent equilibrium dissociation constants (K^) and
STRIATUM M ESO LIM B IC A R E A
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Fig. 1. The effect of long-term treatm ent (for 15 days) with haloperidol, clozapine and BMY 14802 on 5H-spiperone binding in (ц 
striatum and mesolimbic region.
Part A -  the apparent density and part В -  the apparent affinity of dopamine^ receptors. B„„ -  density of binding sites; - dissot 
constant. * -  P < 0 .05  compared to saline treated animals (Student’s t-test). SAL =  saline, HAL =  haloperidol, CLZ =  clozapine, BMY 
BMY 14802.
RECEPTORS FOR ANTIPSYCHOTIC DRUGS 135
maximum number of binding sites (Bm„) were calculated from bind­
ing studies performed 72 hr after the last injection of test drugs using 
a non-linear iterative computer curve-fitting program (Enzfitter) of 
Leatherbarrow (1987).
The ICS„ values for haloperidol, clozapine and BMY 14802 were 
detected using the methods described above. The concentrations of 
3H-spiperone, 3H-halopendol and !H-TCP used in displacement 
experiments were respectively 0.1 nM, 1.7 nM  and 2 nM. Ten 12 
concentrations of test compounds were used to inhibit sH-ligand 
binding. The experiments were repeated at least 4 times. The IC*, 
values were determined by log-plot analysis.
Results
A s sh o w n  in the table 1, the studied drugs inhibited drug- 
induced behaviour in the following order of potency: halop- 
eridol $> clozapine> BMY 14802. All three compounds had 
the lowest ED50 value against yawning induced by a low 
dose (0.1 mg/kg) of apomorphine (table 1). It is worth 
noting that clozapine was a relatively more effective antag­
onist of MK-801-induced motor excitation as compared to 
its action against amphetamine-induced locomotor stimula­
tion. A nearly 3-fold lower dose of clozapine was needed to 
antagonize the effect of MK-801 (ED50 value 6.4 nmol/kg) 
compared with the action of amphetamine (ED50 value 17 
(imol/kg). By contrast, haloperidol and BMY 14802 did not 
differentiate between the locomotor effects of amphetamine 
and MK-801. Very similar doses of haloperidol, as well as 
BMY 14802, were effective against amphetamine and MK- 
801 (table 1). Clozapine and BMY 14802, differently from 
haloperidol, were unable to inhibit apomorphine-induced 
stereotyped behaviour in the rat. Clozapine at higher doses 
(>31 ц т о 1/kg) even increased the intensity of apomorph- 
ine-induced gnawing stereotypies (data not shown). BMY 
14802 did not block apomorphine-induced aggressiveness. 
In the radioligand binding studies haloperidol was the most 
potent inhibitor of 3H-spiperone binding at dopamine2 re­
ceptors in the rat striatum, while clozapine was only a 
moderately potent compound and BMY 14802 had only a 
very weak interaction with dopamine2 receptors (table 1). 
In 3H-haloperidol binding studies at sigma sites (the binding 
was performed in the presence of a selective antagonist to 
dopamine, receptors -  raclopride) in the rat frontal cortex
haloperidol had significantly higher affinity in comparison 
with BMY 14802. Clozapine was ineffective in antagonizing 
3H-haloperidol binding at sigma sites (table 1). All three 
compounds studied (up to 100 цМ) were completely ineffec­
tive against 3H-TCP binding in rat frontal cortex (data are 
not shown). The ratio between IC50 values of clozapine and 
haloperidol against ’H-spiperone in the rat striatum was 
very similar to the ratio between ED50 values of clozapine 
and haloperidol against apomorphine-induced climbing, 
amphetamine-induced motor excitation and apomorphine- 
induced aggressiveness (table 1). A very similar relation was 
found between the IC50 values of haloperidol and BMY 
14802 against 3H-haloperidol binding in the rat frontal cor­
tex and their ED ^ values against apomorphine-induced 
yawning, amphetamine-induced motor excitation and MK- 
801-induced motor excitation (table 1).
MK-801 (0.2 mg/kg) caused stereotyped behaviour (sniff­
ing, head movements, circling behaviour, but never gnawing 
stereotypies) and ataxia in the rat. Simultaneously MK-801 
increased the number of line crossings, but decreased the 
number of rearings in the open field (table 2). Long-term 
treatment (15 days) with haloperidol (0.5 mg/kg daily), 
clozapine (10 mg/kg daily) and BMY 14802 (10 mg/kg 
daily) did not change the stereotyped sniffing and ataxia 
induced by MK-801. Repeated treatment with clozapine 
significantly enhanced the effect of MK-801 on line cross­
ings and nearly restored the number of rearings suppressed 
by MK-801 (table 2). Long-term treatment with haloperidol 
and BMY 14802 also increased to some extent the loco­
motor effect of MK-801, but this increase was statistically 
insignificant. The administration o f apomorphine (0.15 mg/ 
kg) induced stereotyped gnawing behaviour and significant­
ly decreased the motor activity in saline treated animals 
(table 3). Apomorphine decreased the number of line cross­
ings, rearings and head-dips in the open field test. The 
chronic pretreatment with clozapine and BMY 14802 anta­
gonized completely the motor depressant effect of low dose 
of apomorphine. Long-term treatment with clozapine, dif­
ferently from haloperidol and BMY 14802, reduced the 
intensity of stereotyped gnawing behaviour in the rat. The 
chronic treatment with haloperidol also attenuated to some
□  S A L
FRONfTAL C O R T E X  HIPPO CA M PUS F  C O R TE X  H P P O C A M P U S
Fig. 2. The effect of long-term treatment (for 15 days) with haloperidol, clozapine and BMY 14802 on 3H-TCP binding in the rat frontal
cortex and hippocampus (see also explanation to fig. 1).
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Fig. 3. The effect o f  long-term treatm ent (for 15 days) with haloperidol, clozapine and BMY 14802 on 3H-haloperidol binding in the rat 
frontal cortex and cerebellum (see also text to fig. I).
extent the motor depressant effect of apomorphine, but only 
the antagonism to the decreased number of head-dips was 
statistically significant (table 3).
The density of apparent binding sites for 3H-spiperone in 
the striatum and mesolimbic area (nucleus accumbens and 
tuberculum olfactorium) was 22.8+1.2 and 7.5 +  0.8 fmol/ 
mg wet weight tissue, respectively. The dissociation constant 
for 3H-spiperone was 0.17±0.01 nM in the striatum and
0.08 + 0.01 nM in the mesolimbic structures. Repeated treat­
ment with haloperidol significantly increased the apparent 
number and reduced the affinity of 3H-spiperone binding 
sites in the striatum and mesolimbic area (fig. 1). The affinity 
of !H-spiperone binding sites in mesolimbic structures also 
decreased to some extent after long-term treatment with 
clozapine. The elevation of 3H-spiperone binding sites’ den­
sity induced by repeated administration of clozapine and 
BMY 14802 was not statistically significant. The apparent 
number of binding sites for ’H-TCP in the frontal cortex 
and hippocampus was 115 + 8 and 142 ±  13 fmol / mg original 
tissue wet weight, respectively. The dissociation constant for 
3H-TCP was 7.0+ 1.5 nM in the frontal cortex and 10.1 +  1.4 
nM in the hippocampus. Only the long-term administration 
of clozapine induced the increase of 3H-TCP binding sites’ 
density in the rat frontal cortex, whereas BMY 14802 and 
haloperidol were ineffective (fig. 2). The apparent number 
of binding sites for 3H-haloperidol (in the presence of 500 
nM raclopride) in the frontal cortex and cerebellum was 
336 + 20 and 410±32 fmol/mg original tissue wet weight, 
respectively. The dissociation constant fot 3H-halopridol 
was 7.8 + 0.8 nM in the frontal cortex and 15 +  2.5 nM in 
the cerebellum. The long-term treatment with BMY 14802 
increased the density and decreased the affinity of 3H-halop- 
eridol-labelled sigma receptors in the frontal cortex (fig. 3). 
By contrast, chronic treatment with haloperidol decreased 
like BMY 14802 the affinity of sigma sites in the frontal 
cortex (fig. 3), but differently from the selective sigma antag­
onist, haloperidol reduced the density of sigma sites in the 
cerebellum nearly 50% (from 410 ±  32 to 215121 fmol/ 
mg original tissue wet weight). Long-term treatment with 
clozapine did not cause any statistically significant changes 
in 3H-haloperidol binding at sigma receptors (fig. 3).
Discussion
According to the present study, haloperidol is significantly 
more potent than clozapine and BMY 14802 in blocking 
the behavioural effects of amphetamine, apomorphine and 
MK-801, and in inhibiting 3H-radioligand binding at dop- 
amme2 and sigma receptors. Despite the significant interac­
tion of haloperidol with sigma receptors in in vitro binding 
studies, it is rather doubtful that these receptors are playing 
the main role in the action of haloperidol. Haloperidol 
evidently antagonizes the behavioural effects of dopamine 
agonists (apomorphine and amphetamine) and after long­
term treatment induces the up-regulation of dopamine2- 
receptors in the striatum and mesolimbic structures. There­
fore, it is most likely that the dopamine2 receptor is the 
main target for the action o f haloperidol. Nevertheless, 
evidence exists that sigma receptors modulate the activity 
of dopaminergic neurones (Steinfels & Tam 1989). The re­
sults of the present study seem to support this opinion to 
some extent. Indeed, the selective sigma antagonist BMY 
14802 antagonized apomorphine-induced yawning and am­
phetamine-induced motor excitation -  the behavioural ef­
fects related to the presynaptic dopaminergic mechanisms 
(Anden 1970; Stable & Ungerstedt 1984; Stoessel et al.
1987). By contrast, BMY 14802 was completely ineffective 
against apomorphine-induced stereotyped behaviour and 
aggressiveness, where probably the postsynaptic dopamine 
receptors are involved (Seeman 1980; our unpublished data). 
The results of long-term treatment with BMY 14802 and 
haloperidol also seem to support the idea about the func­
tional interaction between dopamine neurons and sigma 
receptors. Repeated treatment with haloperidol and BMY 
14802 caused different changes in the binding of ^ -sp ip e ro ­
ne and 3H-haloperidol in the rat brain, but very similar 
changes at the behavioural level. In behavioural experiments 
long-term treatment with haloperidol and BMY 14802 simi- 
larily reversed the motor depressant effect o f apomorphine 
(0.15 mg/kg), but enhanced moderately the motor stimulant 
effect of MK-801. Different from haloperidol, the long­
term administration of BMY 14802 failed to change the 
parameters of 3H-spiperone binding, but increased the den­
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sity of sigma sites in the rat frontal cortex. M a n a llac k  & 
Beart (1988) have shown similar up-regulation of rat cortical 
sigma receptors after subchronic administrations (for 5 or 
7 days) of putative sigma antagonists, rimcazole and 1,3- 
di(2-tolyl)guanidine. By contrast, repeated administration 
of haloperidol reduced significantly the density of sigma 
sites in the cerebellum. This finding is in good agreement 
with the study of Itzhak & Alerhand (1989) where also 
the inhibition of ( +  )-3H-3-PPP labelled sigma sites was 
established in the mouse brain after repeated treatment 
by haloperidol. In electrophysiological studies the chronic 
administration of BMY 14802 suppressed the activity of 
mesolimbic, but not of nigrostriatal dopaminergic neurons 
(Wachtel & White 1988). This effect of BMY 14802 re­
sembles very much the action of atypical neuroleptic drugs 
(i.e. clozapine) (Chiodo & Bunney 1983).
Clozapine, differently from haloperidol and BMY 14802, 
antagonized at relatively low dose the MK-801-induced 
hyperlocomotion. Furthermore, clozapine potently reversed 
M^-801-induced stereotypy in rats whereas haloperidol 
only delays its onset and duration (Tiedtke et al. 1990). 
Taking into consideration the finding of Janowsky & Berger 
(1989) that clozapine is an effective inhibitor of 3H-MK-801 
binding at PCP receptors, it is possible that this anti-MK- 
801 effect is explainable by the direct interaction of clozapi­
ne with PCP binding sites at NMDA receptors. However, 
our experiments do not support this opinion, clozapine even 
in concentrations of up to 100 цМ was not able to inhibit 
3H-TCP binding. Nonetheless, repeated treatment with cloz­
apine, differently from the action of haloperidol and BMY 
14802, increased significantly MK-801-induced hyperloco­
motion. This behavioural phenomenon was parallel to the 
up-regulation of PCP binding sites in the rat frontal cortex 
after chronic administration of clozapine, i.e. repeated treat­
ment with clozapine induced hypersensitivity at PCP bind­
ing sites inside the NMDA receptor channel. Long-term 
treatment with clozapine did not change significantly the 
density of dopamine2 receptors, however, the involvement 
of dopamine2 receptors in the action of clozapine also seems 
to be obvious. A good relation exists between the ratio 
of ICso values of clozapine and haloperidol at dopamine2 
receptors in the rat striatum and their EDM values in the 
behavioural experiments (apomorphine-induced climbing 
and aggressiveness, amphetamine-induced motor exci­
tation). Clozapine is a relatively active and selective antag­
onist of apomorphine-induced yawning and aggressiveness. 
Apomorphine-induced yawning and aggressiveness are 
probably related to the stimulation of dopamine2 receptors 
(Yamada et al. 1986; our unpublished data).
In conclusion, it is probable that not only dopamine2 
receptors, but also sigma and PCP receptors may be in­
volved in the action of antipsychotic drugs. Evidence exists 
that the selective sigma antagonist BMY 14802 decreases 
activity of dopamine neurones by blocking the sigma recep­
tors (Wachtel & White 1988). Nevertheless, according to the 
present study the action of BMY 14802 was significantly 
weaker as compared to haloperidol and clozapine, the clini­
cally effective antipsychotic drugs. Therefore, it is rather 
doubtful that BMY 14802 will be a strong antipsychotic 
drug. Kane et al. (1988) have shown that clozapine is an 
effective drug in the medication of schizophrenic patients 
resistant to conventional antipsychotic treatment. Thus, one 
could speculate that the indirect interaction with PCP bind­
ing sites has some significance in the beneficial clinical ac­
tion of clozapine.
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Abstract: We compared antipsychotic drugs (haloperidol, chlorpromazine and clozapine) and о  antagonists (remoxipride, 
cinuperone, a-(4-fluorophenyl)-4-(-fluoro-2-pyrimidinyl)-l-piperazine butanol (BMY 14802) and rimcazole) in the radio­
ligand binding and behavioural experiments in rodents. A good correlation was established between the affinity o f com ­
pounds at dopamm e2-receptors in the striatum  and their ability to block apomorphine-, amphetamine- and quipazine- 
induced behavioural effects in rodents. By contrast, no correlation was found between the behavioural effects of these 
drugs and their affinity at dopamine,-. 5-HTr  and a  receptors. The rank order o f potency among the studied antipsychotic 
drugs in the behavioural tests and at dopamine2-receptors was following: haloperidol*»chlorpromazinesclozapine. The 
effectiveness o f chlorpromazine and clozapine was nearly similar against apomorphine-induced aggressiveness and yawn­
ing, whereas at 5-HT2-receptors clozapine was more active than chlorpromazine. The weak activity of a  antagonists at 
dopamine2 receptors could be a possible reason why these compounds were less effective in the behavioural studies 
compared to antipsychotic drugs. However, the antagonism of remoxipride against apomorphine-induced stereotypy and 
aggressiveness is not related to its activity at a  receptors, because the other a  antagonists did not block these effects of 
apomorphine. It is probable that remoxipride exerts its action through blocking o f dopamine2 receptors. In conclusion, 
the present study revealed only weak activity of a  antagonists in the behavioural models widely used to study the antipsy­
chotic drugs. Therefore, the antipsychotic activity o f  a  antagonists is doubtful.
It is generally accepted that the clinical potency of antipsy­
chotic drugs is related to their affinity at dopamine2-recep- 
tors in the striatum (Seeman et al. 1976). However, the anti­
psychotic drugs do not interact only with dopamine2-recep- 
tors, but they also share high affinity for the other receptors 
occurring in the mammalian brain (for example dopamineb 
5-HT2, muscarinic, a-adrenergic, a  etc.). Nevertheless, the 
role of these receptors in the action of antipsychotic drugs 
remains still to be established.
Recently, a new group of purported antipsychotic drugs, 
displaying significantly higher affinity for cr than dopamine2- 
receptors, has been developed (Largent et al. 1988). Several 
a  antagonists, like rimcazole (Ferris et al. 1986), cinuperone 
(Su 1986) and a-(4-fluorophenyl)-4-(-fluoro-2-pyrimidinyl)- 
1-piperazine butanol (BMY 14802) (Taylor & Dekleva 
1988), has been characterized in the behavioural experi­
ments as the ‘atypical’ antipsychotic compounds. Moreover, 
the significant relationship bwteen a  receptors and dop­
aminergic neurones has been established in the brain 
(Steinfels & Tam 1989). The localization of a  receptors on 
the mesencephalic dopamine neurones was shown in auto­
radiographic binding studies (Graybiel et al. 1989). The ad­
ministration of the a  agonist (+)SK F 10,047 (N-allylnor- 
metazocine) stimulates the activity of dopamine cells in the
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Tartu University, Ülikooli 18, EE-2400 Tartu, Estonia (fax 372-7- 
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ventral tegmental area (Freeman & Bunney 1984). Rimca­
zole, an antagonist of a  receptors, effectively antagonizes 
(+)SK F 10,047-induced excitation of dopamine neurones 
(Ceci et al. 1988). In addition, long-term treatment with the 
selective a  antagonist BMY 14802, like that of the ‘atypical’ 
antipsychotic drug clozapine, reduces the number of spon­
taneously active dopamine cells in the ventral tegmental 
area without affecting the activity of dopamine cells in the 
substantia nigra (Wachtel & White 1988).
Considering the possible antipsychotic activity of о an­
tagonists, in the present study, an attempt was done to com­
pare the effects of various clinically effective antipsychotic 
drugs (haloperidol, chlorpromazine, clozapine) with that of 
the preferential a  antagonists (rimcazole, remoxipride, cinu­
perone, BMY 14802). The first part of experiments was 
dedicated to reveal the interaction of all these drugs with 
dopamine p, dopamine2-, 5-HT2- and cr receptors, because 
all these receptors were shown to be involved to some extent 
in the action of various antipsychotic drugs. Simultaneously 
with the radioligand experiments, the behavioural studies 
were employed. The action of antipsychotic drugs and a 
antagonists was studied upon the behavioural effects of 
drugs interacting with dopamine- and 5-HT-receptors (apo­
morphine-induced climbing and amphetamine-induced 
hypermotility in mice, apomorphine-induced aggressive­
ness, stereotypy and yawning behaviour, and quipazine-in­
duced head-twitches in rats). The selection of these behavi­
oural models was motivated by the wide use of these behavi­
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oural models in the preclinical screening of drugs with 
possible antipsychotic activity.
Materials and Methods
Animals. Male albino rats, weighing 250-300 g, and male albino 
mice, weighing 25-30 g, were used in the experiments. The animals 
were kept under standard laboratory conditions (temperature 
20±3°), with free access to food and water. Mice were used in apo- 
m orphine-induced climbing and amphetamine-induced hyperloco­
m otion experiments. Rats were employed in the following tests: 
apomorphine-induced aggressiveness, stereotypy and yawning be­
haviour, and quipazine-induced head twitches.
Drugs. The commercial solution o f  haloperidol (Gedeon Richter, 
Hungary) was diluted in saline immediately before o f the experi­
ment. Remoxipride (Astra AB, Sweden), rimcazole (Burroughs- 
Wellcome, U.S.A.), BMY 14802 (a-(4-fluorophenyl)-4-(-flouro-2-py- 
rimidinyl)-1 -piperazme butanol) (Bristol-Myers & Squibb, U.S.A.) 
and chlorpromazine (Sigma, U.S.A.) were dissolved in saline, 
whereas clozapine (Sandoz, Switzerland) and cinuperone (Hoechst, 
Germany) were suspended in the saline with the help of 1-2 drops 
o f Tween-85.
Behavioural studies.
Amphetamine-induced motor excitation was measured in individual 
cylindrical cages (diameter 40 cm), with 2 photocells located in the 
wall (Vasar et al. 1990). Locom otor activity was counted between 
15 and 45 min. after the administration o f d-amphetamine (Sigma, 
U.S.A., 5 mg/kg, subcutaneously). The test compounds were in­
jected 30 min. before the measurement o f m otor activity.
Apomorphine-induced climbing was studied according to the 
method of M oore & Axton (1988): apomorphine (Sigma, U.S.A., 3 
mg/kg, subcutaneously) and test compounds were given respectively 
5 min. and 30 min. before the placement of animals into individual 
wire net cages, where the climbing activity was registered during 30 
min.
Apomorphine-induced stereotyped behaviour. Apom orphine (0.5 
mg/kg, subcutaneously) was injected 30 min. and the test drugs 60 
min. before the registration o f stereotyped behaviour according to 
the scale of Costall & Naylor (1974). Stereotyped behaviour was 
detected simultaneously with aggressive behaviour.
Apomorphine-induced aggressiveness was studied in grouped ani­
mals ( 8  rats in the test cage). The animals were sensitized previously 
to  apomorphine aggressiveness by 2 -weeks repeated treatment with 
apomorphine (0.5 mg/kg, twice daily, subcutaneously) (Allikmets & 
Vasar 1982). The number o f rats exhibiting the aggressive behaviour 
(aggressive posturing, boxing, biting, vocalization etc.) after the ad­
m inistration of apomorphine (0.5 mg/kg, subcutaneously) was 
registered. All the drugs in the study were injected 30 min. before 
treatm ent with apomorphine.
Apomorphine-induced yawning. The rats were tested according to 
method o f Morelli et al. (1986). The number o f yawns was counted 
during 1 hr after treatm ent with apomorphine (0 .1  mg/kg, subcu­
taneously). a  Antagonists and antipsychotic compounds were in­
jected 30 min. before the administration o f  apomorphine.
Quipazine-induced head twitches. Head twitches were induced by 
quipazine, an agonist at 5-HT-receptors (Vetulani et al. 1980). The 
number o f head twitches was registered during 30 min. after the 
administration o f quipazine (2.5 mg/kg, intraperitoneally). The 
compounds in the study were injected intraperitoneally 30 min. be­
fore treatment with quipazine.
The ED 30 values for all drugs were calculated from the log dose- 
response curves. However, in the case o f apomorphine-induced 
stereotypy and aggressiveness the dose o f drug was detected com­
pletely blocking these behavioural effects o f apomorphine.
Radioligand binding studies.
For in vitro binding studies the membranes prepared from the vari­
ous brain structures of the rat were used. Animals were killed by 
decapitation. The brains were rapidly removed from the skull and 
the brain structures were dissected on ice. The striatum  was used 
for [3H]-spiperone and [3H]-SCH 23390, the cerebellum for [3H]- 
haloperidol, and the frontal cortex for [3H]-ketanserin binding 
studies. Pooled brain structures from 6  rats were homogenized with 
a Potter-S homogenizer in 20 vol. ice-cold 50 mM Tris-HCl buffer 
(pH 7.4, a t 4°). M embranes were washed twice by the centrifugation 
at 48000 Xg for 15 min. After the last centrifugation the crude mem­
branes were suspended in the incubation buffer for the appropriate 
binding assay.
[ гН ]-Spiperone binding. [3H]-Spiperone (109 Ci/mmol, Amersh- 
am, final concentration 0.1 nM) was incubated 30 min. at 37° with 
the striatal membrane preparation (1 mg wet weight/tube) in 0.5 ml 
of incubation buffer, consisting of Tris-HCl 50 m M, NaCl 120 mM, 
KC1 5 mM, CaCl2 2 mM, M gCli I mM (pH 7.4). The non-specific 
binding was detected in the presence of 10 цМ raclopride. The reac­
tion was stopped by rapid centrifugation at 1 l,000xg  for 4 min.
f 3H J-SC H  23390 binding. Incubation o f the rat striatal mem­
branes (1 mg wet weight/tube) was carried out in 0.5 ml o f incuba­
tion buffer (Tris-HCl, 50 mM, pH 7.4) during 45 min. with [3H]- 
SCH 23390 (Amersham, 85 Ci/mmol, 2 nM) at room temperature. 
The non-specific binding was detected in the presence o f  10 цМ 
SCH 23390. The reaction was stopped by rapid centrifugation at 
11,000 Xg for 4 min.
[ 3H ] -Haloperidol binding. The rat cerebellar membranes (12 mg 
wet weight/tube) were incubated with 1.7 nM o f [3H]-haloperidol 
(8.9 Ci/mmol, D upont-NEN ) in the absence and presence o f 10 цМ 
haloperidol. Spiperone (50 nM) was added to each tube to block 
[3H]-haloperidol binding to dopamine2-, 5-HT2-, a ! adrenergic re­
ceptors. It should be noted that the affinity of spiperone at о  recep­
tors is only in low micromolar range (Tam & Cook 1984). The in­
cubation was carried out at the room temperature in the total vol­
ume of 1 ml 50 mM Tris-HCl buffer (pH 7.7). After a 90 min. 
incubation at room temperature m embrane-bound [3H]-haloperidol 
was separated from free radioligand by rapid filtration through 
W hatm an GF/B glass fibre filters presoaked with 0.05% polyethy- 
leneimine. After filtration, the filters were washed twice (4.5 ml 
each) with incubation buffer.
pH]-Ketanserin binding. Binding o f [3H]-ketanserin (Dupont- 
NEN, 72.3 Ci/mmol, 1 nM) to frontal cortex membranes (2 mg wet 
weight/tube) was performed in the total volume o f 1 ml 50 mM 
Tris-HCl buffer (pH 7.4) at room temperature. To detect non-speci­
fic binding ketanserin (10 цМ) was used. After 30 min. incubation 
the reaction was stopped as described earlier with [3H]-haloperidol 
binding.
Ten to twelve concentrations o f test compounds were used to in­
hibit [3H]-ligand binding. The radioactivity o f samples was meas­
ured by means o f liquid scintillation spectrometry, at 50 per cent 
efficiency level. The IC 50 values for test compounds were deter­
mined by log-plot analysis. The experiments were repeated a t least
4 times. The Spearman rank correlation test was employed to reveal 
the relation between the affinity of drugs at various receptors and 
their behavioral effects.
Results
The results of the bindiftg studies are presented in table 1. 
All tested compounds exerted certain affinity at dopamine2- 
receptors labeled with [3H]-spiperone. Haloperidol was the 
most potent antagonist of [3H]-spiperone binding to dop- 
amine2-receptors, inhibiting it at a low nanomolar level. 
Chlorpromazine and especially clozapine were less effective 
inhibitors of [3H]-spiperone binding in the striatum. By
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Inhibition of in vitro radioligand binding by antipsychotic drugs and a  antagonists.
Radioligand 
Binding site
Spiperone
Dopamine2
SCH 23390 
Dopamine,
Haloperidol
G
Ketanserin
5-HT2
Drug
Haloperidol 5.5±0.8
0\+10 1.1 ±0.4 200±18
Chlorpromazine 16±2.9 400 ±60 200± 13 67±4.2
Clozapine 300+25 210±42 > 1 0 0 0 0 28 ±1.3
Remoxipride 1400±110 > 1 0 0 0 0 120± 13 > 1 0 0 0 0
Cinuperone 76± 13 6200±550 54 ±3.9 0 1 + OO
BMY 14802 5100±420 > 1 0 0 0 0 90±9.7 > 1 0 0 0 0
Rimcazole 5200±530 > 1 0 0 0 0 260 ±29 2300 ±290
Results are presented as IC50 values±S.E.M . in nM.
variance from antipsychotic compounds the IC50 values of 
a  antagonists (remoxipride, BMY 14802 and rimcazole) 
against [3H]-spiperone binding were in micromolar range. 
An exception among a  antagonists was cinuperone, which 
was a potent inhibitor of [3H]-spiperone binding (IC50=76 
nM) to dopamine2-receptors in the present experiments.
The antipsychotic drugs haloperidol, chlorpromazine 
and clozapine displayed only moderate affinity at dop­
amine! receptors (ICjo=210-400 nM) labeled with [3H]- 
SCH 23390 (table 1). High concentrations of cinuperone, 
BMY 14802, remoxipride and rimcazole (>10 pM) were 
needed to block [3H]-SCH 23390 binding at dopaminei- re­
ceptors. Most of tested compounds (haloperidol, chlor­
promazine, remoxipride, cinuperone, BMY 14802, rimcazo­
le) were more effective at dopamine2- than at dopamine, - 
receptors, the only exception was clozapine having nearly 
similar affinity at both dopamine receptors.
The studying of drug potencies at 0 receptors showed the 
inability of clozapine to inhibit the specific binding of [3H]- 
haloperidol to о  receptors in the cerebellum up to the con­
centration of 10 pM, whereas all the other tested com­
pounds had IC50 values less than 300 nM (table 1). Again, 
haloperidol was by far the most potent antagonist (IC50=
1.1 nM) of [3H]-haloperidol binding to a  receptors in the 
rat cerebellum. Remoxipride, BMY 14802, rimcazole and 
cinuperone were apparently more potent at a  receptors 
compared to the other receptors studied.
Chlorpromazine and clozapine displayed a significant af­
finity at 5-HT2-receptors labeled with [3H]-ketanserin (table 
1). Haloperidol and cinuperone exerted moderate activity 
at these 5-HT-receptors (IC50 values 200 and 240 nM, re­
spectively), whereas the remaining compounds had IC50 
values higher than 10 pM.
The EDso values of drugs against the behavioural effects 
of apomorphine, amphetamine and quipazine are presented 
in table 2. Generally, a typical antipsychotic drug haloper­
idol was the most effective antagonist in all behavioural ex­
periments done. Chlorpromazine, clozapine and remoxipri­
de were less effective if compared to haloperidol. The rank 
order of potency of these drugs in the behavioural studies 
was following: haloperidol>remoxipride>chlorpromazine 
^clozapine. Remoxipride was more effective in the behavi­
oural tests where dopamine agonists apomorphine and am­
phetamine were used. Differently from haloperidol and 
chlorpromazine it was more selective antagonist of apo­
morphine-induced aggressiveness compared to stereotyped 
behaviour. The comparisön of chlorpromazine and clozapi­
ne revealed that chlorpromazine was stronger antagonist of 
apomorphine-induced climbing and sterotypy, and amphet­
amine-induced hypermotility. Clozapine did not block apo­
morphine-induced stereotypy, but by variance from the 
other antipsychotic drugs even increased the intensity of 
this behaviour. Chlorpromazine and clozapine had nearly 
similar effectiveness against apomorphine-induced aggress­
iveness and yawning behaviour, whereas in the case of qui­
pazine-induced head twitches clozapine was two times more 
potent than chlorpromazine. The later finding was in corre­
lation with their affinity for 5-HT2-receptors labeled by 
[3H]-ketanserin (table 1).
The comparison of cj antagonists and antipsychotic com­
pounds revealed a big difference between these compounds. 
In general, much higher doses of a  antagonists (cinuperone, 
BMY 14802 and rimcazole) were needed to block the above 
described behavioural effects of apomorphine, amphet­
amine and quipazine. Furthermore, the preferential a  an­
tagonists (cinuperone, BMY 14802 and rimcazole) did not 
antagonize apomorphine-induced sterotypy and aggressive­
ness in the rat.
The correlation was established between the affinity of 
drugs at dopamine2-receptors and their effectiveness in the 
various behavioural studies (the correlation coefficients
0.65-0.93, P<0.05). No correlation was found between the 
behavioural effects and affinity of drugs at the other recep­
tors (the correlation coefficients less than 0.30, P>0.1).
Discussion
The present study revealed clear evidence that the potency 
of antipsychotic drugs and 0 antagonists in various behavi­
oural tests correlated with their affinity at dopamine2-recep- 
tors. No correlation has been established between the affin­
ity of drugs at dopamine,-, 5HT2- and 0 receptors and their 
action against apomorphine-, amphetamine- and quipazi­
ne-induced behaviours. Fritz et al. (1993) were also unable 
to establish the correlation between ability of drugs to block
Table 2.
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Antagonism of antipsychotic drugs and о  antagonists to the behavioural effects o f apomorphine, amphetamine and quipazine in rodents.
Drug-induced
behaviour
Apomorphine
stereotypy
Apomorphine
aggressiveness
Apom orphine
climbing
Apom orphine
yawning
Amphetamine
hypermotility
Quipazine
head-twitches
Drug
Haloperidol 0.67 0.67 0.35 0.13 0.37 0.27
0.22-1.3 0.08-0.36 0.26-0.70 0.15-0.67
Chlorpromazine 28 28 5.6 3.9 3.7 3.8
2.5-14 0.56-6.5 1.9-5.9 0.98-15.0
Clozapine >31 31 24 3.4 17 1.9
8.3-46 1 . 1- 8 . 0 10-29 0.24-15
Remoxipride 24 12 4.7 1.7 4.2 15
1.4-16 0.29-3.3 1 .4-8.0 3.8-57
Cinuperone >51 >51 10 15 4.0 0.97
2.1-63 1.8-32 0.60-6.5 0.18-5.3
BMY 14802 >115 >115 45 7.5 30 15
20-67 1.5-14 16-50 9.7-23
Rimcazole >127 >127 127 60 48 > 1 0 2
76-163 34-150 35-61
Results are presented as ED 50 values (|imol/kg) o f  compounds and confidence limits for them. The doses o f  compounds completely blocking 
the behaviour are shown in the case o f apomorphine-induced stereotyped gnawing and aggressiveness.
apomorphine-induced climbing and their potency at a  re­
ceptors. Haloperidol, a widely used antipsychotic drug, was 
the most potent compound to inhibit [3H]-spiperone bind­
ing at dopamine2-receptors in the rat striatum and it also 
displayed the highest effectiveness in the behavioural 
studies. Indeed, haloperidol was very potent at a  receptors 
in the cerebellum, but haloperidol appears to be an agonist 
of a  receptors. It was established that long-term treatment 
with haloperidol induced the down-regulation of a  recep­
tors in the mouse and rat brain (Itzhak & Alerhand 1989; 
Kizu el al. 1991), whereas several о antagonists (rimcazole, 
BMY 14802) caused the opposite effect (Manallack & Beart 
1988; Lang et a. 1992). Thus, it is very unlikely that the 
current behavioural effects of haloperidol are related to the 
blockade of о  receptors.
Chlorpromazine and clozapine were less active at dop- 
amine2-receptors and they were less effective against apo- 
morphine-, amphetamine- and quipazine-induced behavi­
oural effects compared to haloperidol. The rank order of 
potency of antipsychotic drugs at dopamine2-receptors and 
in the behavioural studies was as follows: haloperidol^ 
chlorpromazinesclozapine. However, it should be noted 
that clozapine instead of blocking of apomorphine-induced 
stereotypy even potentiated the intensity of this behaviour. 
Nevertheless, clozapine and chlorpromazine had nearly 
similar effectiveness against apomorphine-induced aggress­
iveness and yawning in rats. However, it is worthy to stress 
that clozapine is clinically more effective antipsychotic com­
pound compared to chlorpromazine (Kane et al. 1988). Re­
cently, very high affinity o f clozapine at one subpopulation 
of dopamine2-receptor family was established. Namely, clo­
zapine displayed a significant activity for dopamine4-recep- 
tors (Van Tol et al. 1991). The marked potency of clozapine 
and chlorpromazine at 5-HT2-receptors should be also 
mentioned. However, clozapine was more potent than 
chlorpromazine to inhibit [3H]-ketanserin binding to 5HT2-
receptors in the rat frontal cortex and to block quipazine- 
induced head twitches. By variance from haloperidol and 
chlorpromazine, clozapine did not interact with a  receptors. 
However, there is some evidence that clozapine can affect 
in some indirect way the function of N-methyl-D-aspartate 
receptor channels (Tiedtke et al. 1990; Lang et al. 1992).
In general, the preferential о  antagonists were apparently 
less effective than antipsychotic drugs to antagonize the be­
havioural effects of apomorphine, amphetamine and quipa­
zine. Nevertheless, there is a growing body of evidence 
about the functional interaction of a  receptors and dop­
aminergic neurones. Indeed, the high density of a  receptors 
has been described on the mesencephalic dopaminergic cells 
(Graybiel et al. 1989). In addition, the administration of 
a  agonists increased the electrical activity o f dopaminergic 
neurones (Freeman & Bunney 1984; Ceci et al. 1988; 
French & Ceci 1990) and facilitated the release o f dopamine 
(Patrick et al. 1993). The a  agonist-induced increase o f elec­
trical activity of dopamine neurones was potently antagon­
ized by the selective a  antagonist rimcazole (Ceci et al.
1988). The preferential о  antagonist BMY 14802 is shown 
to inhibit dose-dependently the neostriatal motor-depend­
ent neurones in freely moving rats (Wang et al. 1992). Ac­
cording to the present study the preferential о  antagonists 
were effective against apomorphine-induced yawning and 
climbing, amphetamine-induced hyperlocomotion and qui- 
pazine-induced head twitches. However, only remoxipride 
blocked apomorphine-induced stereotyped behaviour and 
aggressiveness, whereas the other a  antagonists were com­
pletely ineffective. In the radioligand binding studies remox­
ipride had nearly tenfold preference for 0 receptors com­
pared to dopamine2-receptors. Recent evidence suggests 
that remoxipride is an apparently more potent drug at dop- 
amine2-receptors than it was established in the present 
study. Indeed, the affinity of remoxipride against [3H]-raclo- 
pride, a highly selective antagonist of dopamine2-receptors,
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was 10 times higher than in our present study, because Kj 
value for remoxipride in this experiment was 113 nM 
(Mohell et al. 1993). The presence of metabolites of remoxi­
pride having moderate affinity for dopamine2-receptors 
could be also a possible explanation for the marked activity 
of remoxipride in the behavioural experiments (Mohell et 
al. 1993). The statement about the significant activity of 
remoxipride at dopamine2-receptors is in good accordance 
with results of Köhler et al. (1990). In contrast to classical 
antipsychotic drugs remoxipride is more potent at prevent­
ing of [3H]-spiperone in vivo binding to dopamine2-recep- 
tors in certain mesolimbic structures and other extrastriatal 
brain areas compared to its effects on striatal binding 
(Köhler et al. 1990). The higher potency of remoxipride 
against apomorphine-induced aggressiveness compared to 
stereotyped behaviour seems also to be related to its higher 
selectivity for limbic dopamine2-receptors. The site of ac­
tion of the other <r antagonists upon the behavioural effects 
of apomorphine, amphetamine and quipazine is less clear. 
However, at least two mechanisms should be considered. 
First, by blocking a  receptors at dopamine cells they could 
decrease the activity o f these neurones. Second, the direct 
interaction of a  antagonists with dopamine2-receptors 
should not be neglected either, because all these drugs (cinu­
perone, BMY 14802 and rimcazole) possessed some activity 
at dopamine2-receptors in the radioligand binding experi­
ments.
It is difficult to explain why cinuperone, having a con­
siderable affinity at dopamine2-receptors in in vitro binding 
studies, displayed weak activity in the behavioural experi­
ments. However, one could speculate that the poor penetra­
tion of cinuperone through the blood-brain barrier would 
be a possible reason. Rimcazole was an effective antagonist 
of apomorphine-induced aggressiveness in earlier studies 
(Ferris et al. 1982), but we were unable to confirm this find­
ing in the present, study. This discrepancy could be ex­
plained in the light of different use of apomorphine, namely 
that Ferris et al. (1982) induced aggressiveness by acute in­
jection o f high dose of apomorphine, whereas in the present 
work the animals were sensitized to aggressive behaviour by 
two weeks pretreatment with apomorphine. Probably, the 
repeated dosing of apomorphine induced the hypersensitiv­
ity of dopamine receptors (Allikmets & Vasar 1982), and 
after that rimcazole, as weak antagonist of dopamine2-re- 
ceptors, was not able to block apomorphine-induced ag­
gressiveness.
In conclusion, the present study revealed only weak activ­
ity of a  antagonists in behavioural models widely used for 
the study o f antipsychotic drugs in rodents. Therefore, the 
antipsychotic activity of a  antagonists is doubtful. This 
pessimistic view is in accordance with the recent clinical 
studies where rimcazole, by contrast from remoxipride (Den 
Boer et al. 1990), did not show any considerable antipsy­
chotic action in schizophrenic patients (Borison et al. 1991). 
However, the data of our experiments favour the existing 
view that the blockade of dopamine2-receptors is a common 
feature in the action of antipsychotic drugs.
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Abstract We studied the aggressive behaviour induced 
by repeated treatm ent with apom orphine, a dopam ine 
agonist (0.5 m g/kg s.c. twice daily, 10 days), in rats. The 
first signs of defensive aggressiveness appeared on the 
third day of apom orphine treatm ent and were generally 
seen on the 7th day. Aggressiveness induced by a chal­
lenge dose of apom orphine (0.5 m g/kg  s.c.) on the 11th 
day was antagonized by haloperidol (0.05 and 
0.1 m g/kgi.p .) and clozapine (10 m g/kgi.p.). An a n ta ­
gonist of N -m ethyl-D -asparta te  (N M D A )-gated chan ­
nels, dizocilpine (M K-801), also blocked the aggressive 
behaviour at 0.25 and 0.5 m g/kgi.p . but caused ataxia. 
W hen dizocilpine (0.25 m g/kgi.p .) and apom orphine 
were coadm inistered for 10 days, aggressive behaviour 
did not develop. At 0.025 m g/kg i.p., dizocilpine even 
accelerated the appearance of apom orphine-induced 
aggressive behaviour, which manifested on the 3rd day 
in all rats. In a separate study, a 7-day treatm ent with 
dizocilpine (0.25-1 m g/kgi.p .) of rats, sensitized by
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a prio r 10-day apom orph ine  treatm ent, did not reverse 
the established aggressive behaviour. The coadm inis­
tra tion  of apom orph ine  and cholecystokinin (CCK) 
-A o r -B antagonists, devazepide o r L-365,260 
(0.01-2.5 m g/kgi.p.) respectively, neither affected devel­
opm ent of apom orphine-induced aggressive behaviour 
nor intensity of aggressiveness in the sensitized rats.
In binding studies neither density nor affinity of 
stria ta l dopam ine D 2 receptors was changed by acute 
o r chronic apom orph ine treatm ent. The num ber of 
[ 3H ]p C C K -8 b inding sites in the frontal cortex in ­
creased already after a single injection of apom orphine. 
After 10-day adm in istra tion  of apom orphine, a signi­
ficant upregulation  of [ 3H ]p C C K -8 binding sites 
occurred in the frontal cortex and stria tum , but 
a dow nregulation  was observed in the hippocam pus. 
A challenge dose of apom orph ine  (0.5 m g/kg  s.c.) on 
the 1 1th  day of experim ent, norm alized the upregulated 
C C K  receptors in the frontal cortex and striatum . 
Acute apom orph ine  did not change [ 3H ]-M K -801 
binding in the ra t brain. However, in rats treated  for 10 
days with apom orphine, the num ber of N M D A -gated  
channels in open state  was increased in the frontal 
cortex and h ippocam pus. In these rats, a challenge dose 
of apom orph ine (0.5 m g/kg  s.c.) norm alized also the 
increased num ber of [ 3H ]-M K -801 binding sites in the 
frontal cortex.
In conclusion, repeated treatm ent with a pom o­
rphine seems to  modify the function of dopam ine D 2 
receptors w ithout affecting their num ber or affinity. 
The increased num ber of N M D A -gated  channels in 
open state appears to  be related to  this a lte ra tion  of 
dopam ine D 2 receptors. The increased density of 
[ 3H ]p C C K -8 b inding sites in the frontal cortex m ay 
reflect anxiety and fear due to chronic  exposure of rats 
to  apom orphine.
Key words A pom orphine • D opam ine receptors 
N M D A -gated  channels C C K  receptors 
D izocilpine ■ Aggressive behaviour ■ C C K  an tagonists
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Introduction
Long-term  treatm ent with various agonists at 
dopam ine receptors (apom orphine, am phetam ine and 
cocaine) induces increased expression of m otor behav­
iou r in rodents (K arler et al. 1989; V aughn et al. 1990; 
D ruhan  et al. 1993). This sensitization appears as in­
creased m o to r activity in ra ts  and  stereotyped behav­
iou r in mice (K arler et al. 1990; D ruhan  et al. 1993). 
Even the em otional behav iour of ra ts  can be altered by 
repeated adm in istra tion  of dopam ine agonists. The 
acute adm inistra tion  of high doses (above 5 m g/kg) of 
apom orphine, an unselective agonist at dopam ine re­
ceptors, induces aggressive behaviour in rats (Lapin 
and Sam sonova 1968; Schneider 1968; Senault 1970). 
However, after p rio r repeated treatm ents with ap o m o r­
phine, low doses (0.15-0.2 m g/kg) of the dopam ine 
agonist cause defensive aggressiveness in rats (Allik- 
mets and  V asar 1982; P orreca  et al. 1982). C onse­
quently, in the course of long-term  adm in istra tion  of 
apom orphine, an apparen t sensitization develops to 
apom orphine-induced hyperlocom otion  and aggres­
sive behaviour. Induction  of aggressive behaviour by 
apom orph ine  is a well reproducib le phenom enon in 
bo th  male and  female ra ts  (P orreca et al. 1982).
D evelopm ent of increased sensitivity to  apom or- 
phine-induced hyperlocom otion  is m ediated through 
dopam ine D ( receptors (M attingly et al. 1991). H ow ­
ever, there is som e evidence tha t long-term  adm in istra ­
tion  of am phetam ine induced hypersensitivity of 
dopam ine D 2 instead of dopam ine D , receptors (Levy 
et al. 1988). In  addition , the developm ent o f increased 
sensitivity to  am phetam ine-induced hyperlocom otion  
seems to  be related  to  presynaptie, bu t not to  pos­
tsynaptic dopam inergic m echanism s in the m esolim bic 
structures (W ise and Leeb 1993). It is w orth  stressing 
th a t repeated  trea tm en t w ith m etham phetam ine in­
duced a long-lasting decrease of dopam ine up take sites 
in the ra t s tria tum  (N akayam a 1993). In con trast to  
apom orphine-induced hyperlocom otion  dopam ine D 2 
receptors are involved in the m ediation of defensive 
aggressiveness induced by apom orph ine  (Lang et al. 
1992). The clinically effective antipsychotic drugs 
(haloperidol, clozapine, rem oxipride, ch lorprom azine 
etc.) po ten tly  block this behavioural effect of ap o m o r­
phine (Lang et al. 1992, 1994). T he antiaggressive effect 
of antipsychotic drugs is correlated  w ith their affinity at 
dopam ine D 2, but not at dopam ine D b  sigma, 5 -H T 2 
or N M D A -recep tors (Lang et al. 1992). C onsequently , 
apom orphine-induced aggressive behaviour m ay serve 
as an  anim al m odel to  reveal new po ten tia l an ti­
psychotic drugs.
There is a grow ing body of evidence dem onstra ting  
a functional in teraction  between dopam ine receptors 
and  N M D A -gated  channels. N M D A -gated  channels 
seem to  regulate the activity  o f the dopam inergic sys­
tem not only a t the  level of presynaptie m echanism s.
but also by affecting postsynaptic dopam ine receptors. 
Indeed, N M D A -gated  channels are involved in the 
regulation  of dopam ine release and  their stim ulation 
evoked a substantia l release of dopam ine in the 
stria tum  (W ang 1991; C ai et al. 1991). Furtherm ore, 
long-term  adm inistra tion  of dizocilpine (M K-801), 
a noncom petitive an tagon ist of N M D A -gated  chan­
nels, significantly increased the expression of D 2 
dopam ine receptor m R N A  and the density of D 2 
dopam ine receptors in the s tria tum  w ithou t changing 
the presynaptie dopam inergic activity (M icheletti et al. 
1992). O n the o ther hand, the lesion of n igrostriatal 
dopam inergic neurons by m eans of intranigral 6-hy- 
d roxydopam ine injections resulted in an elevated num ­
ber of N M D A -gated  channels in the ra t stria tum  (Sam ­
uel et al. 1990). Recently, it was established tha t the 
coadm in istration  of am phetam ine, cocaine and 
apom orph ine w ith dizocilpine antagonized  the devel­
opm ent of hypersensitivity to  dopam ine agonist in­
duced m o to r excitation (K arler et al. 1989; D ruhan  
et al. 1993). These findings p robably  reflect an 
indirect involvem ent of N M D A -gated  channels in the 
action of dopam ine agonists, and it m ight explain the 
developm ent of hypersensitivity of dopam ine receptors. 
Therefore, studies on the effect of dizocilpine on 
apom orphine-induced aggressive behaviour were 
needed.
C holecystokinin octapeptide (C C K -8), the most 
widely d istributed  neuropeptide in the  brain, has been 
show n to  regulate the activity of the dopam inergic 
system in the limbic structures (Crawley 1991). Two 
subtypes of C C K  receptors (C C K A [peripheral sub- 
type] and C C K B [b rain  subtype] receptors) m ediate 
opposite effects o f C C K -8 on К  +-stim ulated dopam ine 
release from  the nucleus accum bens (M arshall et al. 
1991). M oreover, the application  of C C K -8 in to  the 
posterio r part o f nucleus accum bens (the area where 
C C K A receptors dom inate) enhances the stim ulatory  
action of dopam ine upon the adenylate cyclase activity, 
while C C K  infusions in to  the an te rio r part of nucleus 
accum bens (the area of C C K B receptor dom ination) 
apparently  inhibit this effect of dopam ine (Studler et al. 
1986; M arshall et al. 1991). However, little is know n 
ab o u t the role of C C K  in the developm ent of hypersen­
sitivity to dopam ine agonists. A high dose of caerulein 
( 10 0 ng/kg) a tten u ated  the developm ent of apom or- 
phine-induced aggressive behaviour (Allikmets and 
V asar 1990). Therefore, in the present w ork an a ttem pt 
was m ade using selective CCK  receptor an tagon ists  to 
clarify the role o f C CK  receptors in the aggressiveness 
induced by repeated apom orph ine injections.
W e first exam ined the actions of the noncom petitive 
N M D A  antagonist, dizocilpine, and  selective C C K  an ­
tagonists (C C K B: L-365,260 and  C C K A: devazepide), 
on the intensity of apom orphine-ir.duced aggressive­
ness in ra ts  already sensitized to  apom orphine. 
H aloperidol and clozapine were used as positive con ­
trols. Then we studied the effect of dizocilpine and
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C C K  antagonists on the developm ent of apom or- 
phine-induced aggressive behaviour. In add ition , cha­
nges in the density o f dopam ine D 2, M K-801 labeled 
N M D A -gated  channels and  C C K  receptors were 
studied in the brains o f ra ts  treated  chronically  with 
apom orphine.
Methods
Animals. Male W istar (H an/K uo) rats (National Animal Center, 
Kuopio, Finland), weighing 180-200 g at the beginning of the ex­
periments were kept in home cage in groups of five. The animals 
were m aintained on food (animal pellets) and tap water ad libitum. 
Rats were kept in a tem perature-controlled room  (22 ±  1 C) with 
a 12 h light-dark cycle (lights on: 8:00). Behavioural testing, as well 
as collecting of brain samples for radioligand binding studies were 
carried out between 14:00 19:00.
Behavioural testing. Apom orphine-induced aggressive behaviour 
was studied in grouped rats (8-10  rats together in test cage). The 
animals were labelled before the beginning of experiment. The high­
est score of aggressive behaviour displayed by each rat during the 
observation time was registered. Aggressive behaviour was meas­
ured in a cage with glasswalls, size 55 x 40 x 40 cm. The observation 
was performed 30 min after the adm inistration of apom orphine 
(0.5 mg/kg) during a 5-min observation period on the 1st, 3rd, 7th 
and 10th day of repeated treatm ent with dopamine agonist. Rating 
of aggressive behaviour (Allikmets et al. 1979) was performed on 
a 0 -4  point scale:
0 , no aggressive manifestations; 1, intermittent upright attack pos­
turing and contact with other rat, no vocalizations; 2 , interm it­
tent upright attack posturing and boxing, mild vocalizations; 3, 
continuous upright attack posture, boxing and vocalization; 4, 
continuous fighting and vocalization, attem pts to bite an opponent 
rat.
When the development of aggressive behaviour with the highest 
score (attem pts to bite an opponent animal) occurred, the rats were 
immediately isolated to avoid injuries.
Treatments. Apom orphine (0.5 m g/kg twice daily, at 9:00 and 
17:00) was given subcutaneously for ten days. Dizocilpine (0.01- 
0.5 mg/kg), haloperidol (0.01—0.1 mg/kg), clozapine (1-10 mg/kg), 
L-365,260 (0.01-2.5 mg/kg) and devazepide (0.01-2.5 mg/kg) were 
injected intraperitoneally 30 min before apomorphine. To investi­
gate the effect of dizocilpine (0.025-0.25 mg/kg) and CCK antagon­
ists (0 .0 1 - 1  mg/kg) on the development of apomorphine-induced 
aggressiveness, these drugs were injected 30 min before apom or­
phine for 1 0  days.
In the radioligand binding studies half of the rats (16 rats) 
received injections of saline and the other half injections of apom or­
phine (0.5 m g/kg twice daily) for 10 days. The rats were kept in the 
individual cages during their exposure to apom orphine in order to 
avoid a possible influence of fighting on the param eters of 
radioligand binding. When the behavioural m anifestations of 
apomorphine's action ceased the animals were again transferred into 
their home cage. The same approach was used in the case of 
saline-treated control animals. Thus, twice a day during the expo­
sure to apom orphine and saline (between 9:00-10:00, and between 
17:00-18:00), rats were kept isolated. On the 11th day of the 
experiment, half the animals (8  rats) from both groups (saline and 
apom orphine-treated, respectively) received either saline or apom or­
phine (0.5 mg/kg) injections. Thirty mm after the administration of 
saline and apomorphine, rats were killed by decapitation.
Radioligand binding experiments. Rats were decapitated and the 
brains were quickly dissected. The binding studies were generally
performed on brain structures of individual animals. Only in the 
case of striatum , tissue from two rats was pooled. Brain tissue was 
homogenized in 20 volumes of ice-cold 50 m M  Tris-HCl (pH 7.4 at 
4°C) using a Potter-S glass-teflon homogenizer (1000rpm, 12 
passes). The m embranes were washed twice in the same buffer by 
centrifugation and resuspension. For C C K - 8  binding experiments 
the pellets were homogenized in HEPES buffer (1 0 m M  HEPES; 
130 mM NaCl; 5 mM  KC1; 1 mM EDTA; pH 6.5 adjusted with
5 N NaO H) containing bovine serum albumin (0.5 mg/ml). C C K -8  
receptor labelling was carried out in the presence of 0.05-2.4 nM 
[propionyl-3 H]propionylated-CCK -8 sulphated ( [ 3H ]pC C K -8 , 
specific activity 79 C i/m m ol, Amersham, UK) at room  tem perature 
in a total incubation volume of 0.5 ml. Caerulein (100 nM ) was 
added to determine nonspecific binding. F or [ 3H]-M K-801 
(1-80  nM , specific activity 25 Ci/m m ol, D upont-N EN , USA) bind­
ing, the homogenized m embranes were incubated in Tris-HCl buffer 
(50 mM) at room  tem perature in a total incubation volume of 0.5 ml. 
To detect nonspecific binding, 100 цМ of unlabelled dizocilpine was 
used. Incubation was term inated after 120 min ( [ 3H ]pC C K -8  
binding) or 60 m in ([3H]-M K-801 binding) by rapid filtration over 
W hatm an G F /B  filters using a Brandel Cell Harvester 
(M-24S, USA). The filters were washed with 10 ml cold incubation 
buffer, dried and assayed for radioactivity by liquid scintillation 
spectrometry. F or dopam ine D 2 receptor assay [ 3 H]-spiperone 
(0.03-2 nM , specific activity 109 Ci/m m ol, Amersham, UK) was 
incubated 30 min at 37 С with the striatal m em brane preparation 
(1 mg wet weight/tube) in 0.5 ml of incubation buffer, consisting of 
Tris-HCl 50 mM, NaCl 120 mM, KC1 5 mM , CaCI2 2 mM, M gCl2 
1 mM (pH 7.4). Nonspecific binding was determined in the presence 
of 1 цМ raclopride (Astra, Sweden). The reaction was stopped by 
rapid centrifugation at 11000 x g for 4 min. The protein content was 
m easured according to a modification of the Lowry procedure 
(Markwell et al. 1978). Saturation curves were analyzed using non­
linear least squares regression (Leatherbarrow 1987).
Drugs. Apom orphine hydrochloride (Sigma, USA), dizocilpine 
maleate (formerly MK-801, ( +  )-5-methyl-10, ll-d ihydro-5H - 
dibenzo[a,d]cyclohepten-5,10-im ine maleate, Merck Sharp and 
Dohme, UK), and haloperidol (Gedeon Richter, Hungary) were 
dissolved in saline. Clozapine (Sandoz, Switzerland), CCK antagon­
ists L-365,260 (3R( +  )-N-(2,3-dihydro-l-methyl-2-oxo-5-phenyl- 
lH-l,4-benzodiazepin-3-yl)-N'-3-methyl-phenyl urea) and devazep­
ide (1 -methyl-3-(2-indoloyl)amino-5-phenyl-3H- 1,4-benzodiazepin- 
2-one) (Merck Sharp and Dohme, UK.) were m ade soluble with the 
help of 1-2 drops of Tween-85 (Ferak, Germany).
Statistics. Mean values ±  SEM are presented in table and figures. 
M ann-W hitney U-test was used for evaluation of the behavioural 
data. One-way analysis of variance followed by Duncan's multiple 
range test was used for evaluation of the radioligand binding data.
Result*
D evelopm ent of aggressive behav iour during  repeated  
apom orph ine  treatm ent
The w ell-docum ented acute effects of apom orph ine  
such as sniffing, licking and gnaw ing were seen follow­
ing the first injection of apom orph ine  (0.5 m g/kg). O n 
the th ird  day o f treatm ent the anim als becam e irritab le 
and showed sudden bursts of locom oto r activity  in 
response to  noise o r the app roach  o f an o th e r rat. Some 
rats  also d isplayed upright th reaten ing  posture, sham  
boxing and  vocalization. The ra ts established also 
dom inan t-subo rd ina te  re lationships which did  not
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change th roughou t the du ra tion  o f the observation  
period. F u rth e r adm in istra tions of apom orph ine  ren ­
dered all g rouped ra ts  aggressive by the 7th day  of 
treatm ent. Increasingly vigorous ta il-v ibration  and 
short bursts of locom otion  alw ays preceded this syn­
drom e of aggressive behaviour. These behavioural 
m anifestations occurred  after each injection of ap o m o r­
phine. T he intensity  of aggressive behav iour becam e 
gradually  stronger and  lasted  longer (abou t 45 m in on 
the 10th day o f treatm ent) during  the course o f repeated 
injections with apom orphine. The syndrom e of apom or­
phine-induced aggressive behaviour was very steady. 
O nce induced, any subsequent injection o f ap o m o r­
phine resulted in a  sim ilar behaviour. Even adm in istra ­
tion  o f apom orph ine  3 m onths after the  last injection of 
the 10-day m edication  induced aggressive behaviour.
Effects of single doses o f dizocilpine, haloperidol 
and clozapine w ith a challenge dose of apom orph ine 
in ra ts  sensitized to  apom orph ine
H aloperido l (0.05 and  0.1 m g/kg) and  clozapine 
(10 m g/kg) effectively antagonized the  m anifestation  of 
aggressive behav iour (Fig. 1). U nlike dizocilpine, 
haloperidol also dose-dependently  decreased the 
stereotyped behaviour, w hereas clozapine (10 m g/kg) 
even po ten tia ted  this phenom enon (data  no t shown).
T he adm in istra tion  o f dizocilpine (0.01-0.5 m g/kg), 
a noncom petitive N M D A  an tagon ist, a t doses above 
0.25 m g/kg  blocked the signs o f aggressive behaviour 
caused by apom orph ine  (Fig. 1). H ow ever, this effect of 
dizocilpine was accom panied  by a  m arked  failure of 
m uscular coord ina tion , s tarting  a t 0.25 m g /kg  and  
w orsening a t 0.5 m g/kg.
Dote of drug (mg/kg|
Fig. 1 Effect of dizocilpine (0.01-0.5 mg/kgi.p.), haloperidol 
(0 .0 1 - 0 .1  m g/kg i.p.) and clozapine (1 - 1 0  m g/kg i.p.) on apom or­
phine-induced aggressiveness in rats. The intensity of aggressive 
behaviour was m easured 30 m in after the administration of apom or­
phine (0.5 m g/kg s.c.). Dizocilpine, haloperidol and clozapine were 
given 30 m in before administration of the dopam ine agonist. 
* P < 0 .0 5 ;* *  P c O .O l (M ann-W hitney U-test, compared to sa­
line +  apom orphine treated rats)
Day of apomorphine treatment
Fig. 2 Effect of repeated treatm ent with dizocilpine (0.025-0.25 m g/ 
kg i.p.) and apom orphine upon the development of aggressive be­
haviour. The intensity of aggressive behaviour was assessed 30 min 
after the administration of apomorphine. * P < 0 .0 5 ;  * * P < 0 .0 1  
(M ann-W hitncy U-test, com pared to saline +  apom orphine treated 
rats)
Effect o f coadm in istration  o f dizocilpine and  
apom orph ine  on the  developm ent of aggressive 
behaviour
C oadm in istra tion  (twice daily for 10 days) o f dizocil­
pine (0.25 m g/kg) w ith apom orph ine  (0.5 m g/kg) 
com pletely blocked the developm ent o f aggressive be­
hav iour (Fig. 2). H ow ever, the lowest dose o f dizocil­
pine (0.025 m g/kg) even accelerated the  onset o f aggres­
sive behaviour. A lready on  the th ird  day o f treatm ent 
all ra ts  becam e aggressive if treated  w ith bo th  ap o m o r­
phine and  dizocilpine (0.025 m g/kg; Fig. 2). After com ­
pleting the  experim ent in  w hich dizocilpine 
(0.25 m g/kg) and  apom orph ine  (0.5 m g/kg) were injec­
ted together, the action  o f apom orph ine  was studied. 
The first injection o f apom orph ine  d id  n o t induce any 
signs o f aggressive behav iour in these rats. M oreover, 
the response o f these ra ts  to  repeated  trea tm en t with 
apom orph ine  did  no t differ from  th a t of saline-treated 
anim als. This m eans th a t only on  the  th ird  day  of 
apom orph ine  adm in istra tion  the  first signs o f aggres­
siveness becam e evident.
Effect o f repeated  adm in istra tion  o f dizocilpine 
on aggressive behav iour induced by the p rio r 
10-day apom orph ine  treatm ent
The adm in istra tion  o f dizocilpine (0.25-1 m g /kg  daily 
for 7 days) to  ra ts  sensitized to apom orph ine  did no t 
affect the  increased sensitivity to  apom orph ine  in term s 
of aggressiveness (data  no shown).
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Effect of single doses o f C C K  antagonists on a 
challenge dose of apom orph ine in ra ts  sensitized 
to apom orphine
Single doses of the preferential C C K B receptor a n ta ­
gonist L-365,260 (0.01-2.5 m g/kg) o r the prefere­
n tial C C K A receptor an tagonist devazepide 
(0.01-2.5 m g/kg) were com pletely ineffective against 
apom orphine-induced aggressiveness (data not shown).
Effect of coadm inistration  of C C K  antagonists 
and apom orphine on developm ent o f aggressive 
behaviour
N either L-365,260 (0.01-1 m g/kg) nor devazepide 
(0.01-1 m g/kg) changed the developm ent o f apom or­
phine-induced aggressive behaviour when injected to ­
gether with apom orph ine twice daily for 10 days (data 
not shown).
R adioligand binding experim ents
N either density (Bm„  =  56.8 ±  5.2 fm ol/m g protein) 
nor affinity (K d =  0.48 ±  0.08 nM ) of dopam ine D 2
receptors labelled by [ 3H ]-sp iperone was changed in 
the stria tum  (the num ber of sam ples in each g roup  was 
4) after single (Bm„  =  53.2 ±  6.8 fm ol/m g protein; 
K d =  0.60 ±  0.09 nM ) o r repeated  treatm ent (Bm„  =  
61.2 ±  4.8 fm ol/m g protein ; K d =  0.52 ±  0.10 nM ) of 
ra ts  w ith apom orph ine  (0.5 m g/kg).
A ddition o f apom orph ine  to  the  incubation  m ixture 
(up to  100 цМ ) did  no t affect [ 3H ]-M K -801 and  
[ 3H ]pC C K -8  b inding in the  cerebral cortex o f ra ts  in 
‘in v itro ’ experim ents (data  no t shown).
Acute adm in istra tion  of apom orph ine  (0.5 m g/kg) 
to  saline-treated  con tro l ra ts induced a significant 
increase o f [ 3H ]p C C K -8  binding sites in the  frontal 
cortex, but n o t in the o ther brain  regions studied 
(Table 1).
A pom orphine treatm ent for 10 days increased 
the apparen t density of [ 3H ]p C C K -8  b inding  sites 
in the frontal cortex (F 3i28 =  6.38, P < 0 .0 1 )  and  
stria tum  (F 3 12 =  3.65, P  <  0.05), b u t decreased 
it in the hippocam pus (F 3>28 =  4.12, P  <  0.05) 
(Table 1). After the  sam e treatm ent, the  num ber of 
[ 3H ]-M K -801 b inding sites was a lso significantly 
increased in the  frontal cortex (F 3t28 =  3.80, 
P  < 0.05) and  h ippocam pus (F 3i28 =  3.56, P  <  0.05), 
bu t n o t in the s tria tum  (F 3 i2 =  168, P >  0.05) 
(Table 1).
Table t Effect of repeated 
apom orphine treatm ent on 
[ SH]-MK-801 and 
[ 3H ]pC C K - 8  binding in the 
rat forebrain
Treatm ent
Repeated:
Acute:
Saline
+
saline
Saline
+
apom orphine
Apomorphine
+
saline
Apom orphine
+
apom orphine
[ 3H]-MK-801
Frontal cortex
K .
n =  8 
14.5 ±  0.9 16.6 +  1.1 20.8 +  3.0 15.7 +  0.3
Bmii 2408 ±  136 2578 ±  142 3284 ±216* 2638 ±  204*
Striatum
K„
n =  4 
17.2 +  0.9 15.9 +  2.2 2 1 .8  ±  2 .2 18.5 ±  1.9
1088 ±  98 1028 ±  1 0 2 1356 ± 8 6 1158 ± 9 8
Hippocampus
K .
n =  8  
15.9 ±  1.2 16.7 + 1.6 15.4 ±  1.4 17.4 ±  1.7
Bm„ 1776 ±  178 2048 ±  220 2524 ±  190* 2714 ±  245*
[ 3H]pCCK-8 binding
Frontal cortex 
K ,
n =  8
0.55 ± 0 .1 4 0.72 +  0.19 0.79 ± 0 .1 5 0.58 ±  0.04
Bm.x 12.5 ±  1.0 17.1 ±  1.6* 19.2 ±  2 .0 b 1 2 .6  ±  0 .6 *
Striatum
K„
n =  4
0.71 ±  0.08 0.58 ±  0.05 0.76 ±  0.06 0.58 +  0.06
Bm„ 14.5 ±  1.0 14.2 ±  1.0 17.9 ±  0.8* 1 1 .2  ± 0 .8 *
Hippocampus
K ,
n =  8
0.54 ±0 .0 8 0.53 ±  0.06 0.56 ±  0.06 0.58 +  0.08
8.5 ±  1.0 8.7 ±  1.0 5.6 ±  0.9* 5.2 ±0.7*
The experiment was performed 30 min after the adm inistration o f apom orphine o r saline. The rats were 
pretreated with saline o r apom orphine for 10 days. Results are expressed as m ean values ±  SEM  (Kd in 
nM , Bnlv in fmol/mg protein). *P <  0.05 (compared to saline +  saline), bP < 0 .0 1  (com pared to 
saline +  saline); *P <  0.05 (compared to apom orphine +  saline), n num ber of samples in each group
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A challenge injection of apom orph ine (0.5 m g/kg) 
to  ra ts  previously sensitized to  apom orph ine reduced 
the density  of [ 3H ]p C C K -8 binding sites in the frontal 
cortex and  stria tum  to  the  level of saline-treated  con­
tro l rats. The sam e was true  for [3H ]-M K -801 binding 
in these rats: the adm in istra tion  o f apom orph ine n o r­
m alized the density of [ 3H ]-M K -801 binding sites in 
the frontal cortex. H owever, in the hippocam pus, the 
p aram eters  o f [ 3H ]p C C K -8 and  [ 3H ]-M K -801 b ind­
ing sites rem ained unchanged after a challenge dose of 
apom orph ine  if com pared  to  saline +  apom orph ine 
treated  ra ts  (Table 1).
Discussion
F rom  a m ethodological po in t o f view the present re­
sults are  in good agreem ent w ith the study of Porreca 
et al. (1982) and  ou r previous studies (Allikmets and 
V asar 1982) which showed th a t repeated injections of 
apom orphine, a t m oderate  doses (0.5-1 m g/kg), in­
duced aggressive behav iour in the rats. The intensity of 
aggressive behav iour becam e gradually  s tronger during  
the course o f repeated  injections w ith apom orphine. 
The first signs o f defensive aggressiveness becam e evi­
den t on  the th ird  day o f treatm ent. T he ra ts  becam e 
irritab le and showed sudden bursts  of locom otor acti­
vity in response to  noise o r the app roach  of ano ther rat. 
Som e ra ts also displayed an upright threaten ing  pos­
ture, sham  boxing and  vocalization. O n  the 7th day of 
apom orph ine  trea tm en t all ra ts becam e aggressive. It is 
w orth  stressing th a t the apom orphine-induced aggres­
siveness is very steady. O nce induced, every subsequent 
injection of apom orph ine  caused a sim ilar behaviour. 
Even an acute adm in istra tion  o f apom orph ine 
3 m onths after the last injection of the 10-day ap o m o r­
phine regim en induced the aggressive behaviour.
A pom orphine-induced aggressiveness m ight serve 
as a m odel of psychotic behaviour since several an ti­
psychotic drugs reverse this behaviour (Lang et al. 1992 
1994). In  the present study, a typical an tipsychotic 
drug, haloperidol, and  an atypical antipsychotic com ­
pound, clozapine, bo th  blocked the  aggressive behav­
iour, confirm ing th a t the m odel was w orking. There is 
a  corre la tion  between the  antiaggressive action  of an ti­
psychotic drugs and  their affinity at dopam ine D 2 re­
ceptors (Lang et al. 1994). N evertheless, we were not 
able to  detect any  changes a t dopam ine D 2 receptors 
after repeated  trea tm ent w ith apom orphine. This in 
accordance w ith earlier studies showing th a t the re­
peated adm in istra tion  o f dopam ine agonists did  not 
change the param eters o f s tria ta l dopam ine receptors 
in mice and  ra ts  (Riffee et al. 1982; Jenner e t al. 1988). 
Therefore, o th e r factors m ust be involved.
D izocilpine (0.01-0.5 m g/kg), a noncom petitive 
N M D A  an tagon ist, b locked the aggressive behaviour 
a t doses o f 0.25 m g /k g  o r higher. H owever, the effect
was accom panied by m arked im pairm ent of m o to r 
coordination . Therefore, the specificity of the an tiag­
gressive effect of dizocilpine rem ains questionable at 
this point. N onetheless, coadm in istration  of dizocilpine 
(0.25 m g/kg) with apom orph ine  blocked, w hereas a low 
dose of dizocilpine (0.025 m g/kg) even accelerated, the 
developm ent of aggressiveness. The acute challenge of 
ra ts  with apom orphine, after repeated coadm inistra­
tion  o f apom orph ine and  dizocilpine (0.25 m g/kg), did 
no t cause any signs o f aggressive behaviour. Moreover* 
the response of these ra ts  to  subsequent repeated a d ­
m in istra tion  of apom orph ine did no t differ from  tha t of 
saline-treated rats. The antagonistic  interaction  of 
dizocilpine with apom orphine-induced aggressiveness 
is in good accordance with recent studies which showed 
th a t an  N M D A  antagonist blocked the sensitization 
of ra ts to apom orphine-induced hyperlocom otion 
(D ruhan  et al. 1993). Accordingly, N M D A -gated  chan­
nels are involved in the changes of em otional behaviour 
induced by apom orph ine  as they are in the develop­
m ent of increased m o to r activity. The acceleration of 
appearance of apom orphine-induced aggressiveness by 
0.025 m g/kg  o f dizocilpine is difficult to  explain in the 
light of existing data. T he background  of such an action 
o f dizocilpine is am biguous and  rem ains to  be estab ­
lished.
R epeated adm in istra tion  of apom orph ine increased 
the density  o f [ 3H ]-M K -801 binding sites in two brain 
regions studied (frontal cortex and hippocam pus). 
D izocilpine was show n to  be an  open-channel blocker 
a t N M D A -gated  channels (Sills and L oo 1989). T here­
fore, it is likely th a t apom orph ine treatm ent induced an 
increase in the p ro po rtion  of N M D A  channels in the 
open state ra th e r th an  a true  increase in channel num ­
bers. Acute exposure of these ra ts to  apom orph ine 
induced a m arked dow n-regulation  (to the level of 
con tro l anim als) of [ 3H ]-M K -801 binding sites in the 
frontal cortex and striatum . Therefore, one could 
speculate th a t apom orph ine  induced a significant re­
lease of endogenous ligands for N M D A -gated  channels 
(glutam ate, aspartate), which m ay close these channels.
A bundan t evidence supports  the hypothesis tha t 
C C K -8 affects the activity o f the dopam inergic system, 
especially in the  m esolim bic region (V accarino and 
R ankin  1989; C raw ley 1991). The coadm in istration  of 
the unselective C C K  agonist caerulein (100 ng/kg) with 
apom orph ine  a ttenuated  the developm ent of apom or­
phine-induced aggressiveness in ra ts (Allikmets and 
V asar 1990). H owever, caerulein was unable to  modify 
the already existing hypersensitivity to apom orphine- 
induced aggressive behaviour (Allikmets and  V asar 
1990). Based on electrophysiological findings, R asm us­
sen et al. (1991, 1993) recently proposed th a t C C K B 
an tagonists could display an antipsychotic activity. In 
ou r study, blocking o f C C K  receptors by the C C K B 
receptor an tagon ist L-365,260 (0.01-2.5 m g/kg) and 
the C C K A recep to r an tagon ist devazepide (0.01— 
2.5 m g/kg) neither affected the developm ent nor
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the intensity of apom orphine-induced aggressiveness. 
T aking  in to  account the po ten t in teraction  o f an ti­
psychotic drugs w ith apom orphine-induced aggressive 
behaviour, it is unlikely th a t the currently  existing 
C C K  an tagonists  possess a s trong  antipsychotic action.
Acute adm in istra tion  o f apom orph ine  (0.5 m g/kg) 
to  saline-treated con tro l ra ts induced a significant in­
crease of [ 3H ]p C C K -8 binding sites in the frontal 
cortex, bu t not in the o ther structures. M o ran  et al. 
(1986) have established th a t C C K -8 b inding sites in the 
cerebral cortex belong to  the C C K B receptor subtype. 
It is w orth  no ting  th a t the acute adm in istra tion  of 
apom orph ine (1 m g/kg) also increased the am oun t of 
C C K -8-like im m unoreactivity  in the m edial p refrontal 
cortex (F ukam auchi and T akahash i 1988). Different 
anxiogenic m anipulations o f ra ts  (adm inistra tion  of 
beta-carbolines, exposure of ra ts  to  plus-m aze, ben­
zodiazepine w ithdraw al, social iso lation  o f rats, etc.) 
have sim ilarly been show n to  induce an increase in 
cortical [ 3H ]p C C K -8 b inding (H arro  et al. 1993; V asar 
et al. 1993). Therefore, we suggest th a t the acute tre a t­
m ent w ith apom orph ine  caused an  anxiogenic-like ac­
tion  in rats. F u rth e r adm in istra tions of apom orph ine 
induced even m ore p ronounced  elevation of 
[ 3H ]p C C K -8 binding sites in the frontal cortex and  
striatum , w hereas in the h ippocam pus a decrease of 
these b inding sites was evident. It is likely tha t these 
a ltera tions are a reflection of anxiety and  fear due to 
repeated exposure o f ra ts  to  apom orphine.
In conclusion, the present results suggest tha t 
N M D A -gated  channels play a role in the developm ent 
of apom orphine-induced aggressive behaviour. R epeat­
ed treatm ent w ith apom orph ine  increased the num ber 
o f N M D A -gated  channels in the open state  in the 
frontal cortex and hippocam pus. These changes affect 
the functioning of dopam ine D 2 receptors w ithout a l­
tering their num ber on affinity to  [ 3H ]-spiperone. This 
poorly characterized phenom enon seems to  be the 
m ain reason for the developm ent of apom orph ine-in ­
duced aggressive behaviour. T he role o f C C K  in the 
developm ent of apom orph ine-induced  aggressiveness, 
if any, is p robably  indirect and  the increased density  of 
C C K B receptors in the frontal cortex is likely reflecting 
anxiety and fear due to  chronic exposure o f ra ts  to  
apom orphine.
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